

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Table of Contents

- S1.** Abbreviations
- S2.** Culturing of *Nocardiopsis sp.* CMB M0322 and Extraction of Alkaloidal DKP Metabolites
- S3.** Draft Genome Sequencing of *Nocardiopsis sp.* CMB M0322 and Pathway Annotation, Cloning and Heterologous expression
- S4.** General experimental and instrumentation
- S5.** Table S1. List of chemical structures and corresponding numbers assigned.
- S6.** Synthesis of *cyclo*-L-Trp-L-Trp DKP (5) and its enantiomer *cyclo*-D-Trp-D-Trp DKP (*ent*-5).
- S7.** Asymmetric synthesis of *cyclo*-C3-Me-L-Trp-L-Trp DKP (13)
- S8.** Asymmetric synthesis of *cyclo*-C3-Me-L-Trp-N1'-Me-L-Trp DKP (16).
- S9.** Synthesis of *cyclo*-L-Trp-C3'-ⁿprenyl-L-Trp DKP (12) and *cyclo*-L-Trp-N1'-Me-C3'-ⁿprenyl-L-Trp DKP (15)
- S10.** Conditions for HRMS, HPLC, LC-MS and MS² Characterization and Identification of signature peaks.
- S11.** Figure S1. LC-ESI-TOF MS spectra for biosynthetic intermediates 5, 12, 13, 15 and 16
- S12.** Figure S2. LC-MS of two diastereomers of *cyclo*-L-Trp-C3'-ⁿprenyl-L-Trp DKP (12)
- S13.** Figure S3. MS¹ and MS² for two diastereomers of *cyclo*-L-Trp-C3'-ⁿprenyl-L-Trp DKP (12).

- 34 **S14. Table S2.** MS² fragments for [M]⁺ peak at m/z = 373.1659 corresponding to *cyclo*-L-Trp-
35 L-Trp DKP (**5**).
- 36 **S15. Table S3.** MS² fragments for [M]⁺ peak at m/z = 387.1816 corresponding to *cyclo*-C3-
37 Me-L-Trp-L-Trp DKP (**13**).
- 38 **S16. Table S4.** MS² fragments for [M]⁺ peak at m/z = 401.1972 corresponding to *cyclo*-C3-
39 Me-L-Trp-N1'-Me-L-Trp DKP (**16**).
- 40 **S17. Table S5.** MS² fragments for [M]⁺ peak at m/z = 441.2285 corresponding to *cyclo*-L-
41 Trp-C3'-ⁿprenyl-L-Trp DKP (**12**) .
- 42 **S18. Table S6.** MS² fragments for [M]⁺ peak at m/z = 455.2442 corresponding to *cyclo*-L-
43 Trp-N1'-Me-C3'-ⁿprenyl-L-Trp DKP (**15**).
- 44 **S19. Figure S4.** *cyclo*-L-Trp-L-Trp DKP (**5**). **A.** LC-ESI(-)-TOF-MSMS spectrum from
45 *Nocardioopsis sp.* CMB-M0232. **B.** MS² for extracted **5**. **C.** MS² for synthesized **5**.
- 46 **S20. Figure S5.** LC- ESI+-TOF-MSMS traces from *Nocardioopsis sp.* CMB-M0232
47 confirming presence of tabulated metabolites as given in Table 1 for m/z = 373.2 (**5**);
48 387.2 (**13**) and 574.4 (nocardiopsin A).
- 49 **S21. Figure S6.** LC-ESI (+)-TOF-MSMS traces from *Nocardioopsis sp.* CMB-M0232
50 confirming presence of specific metabolites.
- 51 **S22. Figure S7.** ESI (+)-TOF MS¹ and MS² spectra for m/z = 373.1665 (**5**) extracted from
52 *Nocardioopsis sp.* CMB-M0232.
- 53 **S23. Figure S8.** ESI(+)-TOF MS¹ and MS² spectra for m/z = 387.1791 (**13**) extracted from
54 *Nocardioopsis sp.* CMB-M0232.
- 55 **S24. Figure S9.** LC-ESI+ TOF MSMS spectra for m/z = 469.27 (nocardioazine B, **4**) extracted
56 from *Nocardioopsis sp.* CMB-M0232.

- 57 **S25. Figure S10.** ESI(+)-TOF MS¹ and MS² spectra for m/z = 469.27; nocardioazine B (**4**)
58 from *Nocardiopsis sp.* CMB-M0232.
- 59 **S26. Figure S11.** TLC images of intermediates extracted from *Nocardiopsis sp.* CMB M0322
60 corresponding to alkaloidal fractions.
- 61 **S27. Figure S12.** ¹H NMR spectrum for **13** extracted from *Nocardiopsis sp.* CMB-M0232
62 after 21 days of culture followed by fractionation and purification.
- 63 **S28. Figure S13.** ¹³C NMR spectrum for **13** extracted from *Nocardiopsis sp.* CMB-M0232 –
64 6.9-7.15 ppm.
- 65 **S29. Figure S14.** HPLC analyses of *cyclo*-L-Trp-L-Trp-DKP (**5**).
- 66 **S30. Figure S15.** HPLC analyses of *cyclo*-D-Trp-D-Trp-DKP (*ent*-**5**).
- 67 **S31. Copies of Spectra**
68
69
70

71 **S1. Abbreviations**

72

73	(BOC) ₂ O	-	di- <i>tert</i> -butyl dicarbonate
74	BINOL	-	1, 1'-bi-2, 2'-naphthol
75	BOP-Cl	-	<i>bis</i> (2-oxo-3-oxazolidinyl)phosphonic chloride
76	Cbz-Cl	-	benzyloxycarbonyl chloride
77	NCS	-	<i>N</i> -chlorosuccinimide
78	KOH	-	potassium hydroxide
79	DMAc	-	<i>N,N</i> -dimethylacetamide
80	AIBN	-	2,2'-azobisisobutyronitrile
81	DMF	-	<i>N,N</i> -dimethylformamide
82	NMR	-	nuclear magnetic resonance
83	CD ₃ OD	-	deuterated methanol
84	DKP	-	diketopiperazine
85	TLC	-	thin layer chromatography
86	THF	-	tetrahydrofuran
87	MHz	-	mega Hertz
88	CDCl ₃	-	deuterated chloroform
89	HR-MS	-	high resolution mass spectrometry
90	LC-MS	-	liquid chromatography-mass spectrometry
91	L-Trp	-	L-tryptophan
92	D-Trp	-	D-tryptophan
93	rt	-	room temperature
94	h	-	hour
95	d	-	day(s)
96	satd.	-	saturated
97	anhyd.	-	anhydrous
98	BLASTP	-	Protein Basic Local Alignment Search Tool

99

100 S2. Culturing of *Nocardioopsis* sp. CMB M0322 and Extraction of Alkaloidal DKP**101 Metabolites**

102

103 *Nocardioopsis* sp. strain CMB-M0232, originally-isolated by the Capon group from a sediment
104 sample obtained from South Molle Island from a depth of 55 m¹ was obtained from the Capon
105 laboratory as pure strains of individual colonies. This organism was maintained and propagated
106 for further culturing using standard microbiological techniques. *Nocardioopsis* sp. CMB-M0232
107 were grown to dense colonies on a single agar plate (comprising 25 mL of 1% starch, 0.4% yeast
108 extract, 0.2% peptone, 1.8% agar, and 0.0005% rifampicin) under incubation at 27 °C for four
109 weeks. For larger laboratory culture and for generating extracts, a frozen glycerol stock culture
110 (1.2 mL) of *Nocardioopsis* sp. (CMB-M0232) was used to inoculate a 250 mL Schott flask
111 containing 80 mL of M1 broth (1% starch, 0.4% yeast extract and 0.2% peptone dissolved in
112 deionized water, supplemented with 3% (by weight) ocean salt (Instant Ocean[®], USA). The flask
113 was shaken at 225 rpm in a rotary shaking incubator for ~6-14 d at 27 °C depending on the
114 maturity of each inoculation, as measured by OD₆₀₀. An aliquot of this seed culture (5.0 mL,
115 average OD₆₀₀ = 0.6) was used to inoculate each of six 2 L Schott flasks containing 500 mL of
116 M1 broth, and fermentation was continued for a further 8-21 d (at 27 °C and with rotary shaking
117 at 225 rpm). Following fermentation, the culture was extracted with an equal volume of EtOAc
118 (i.e. 500 mL per flask) and the combined organic phase concentrated *in vacuo* to yield a crude
119 extract (250 mg). The crude extract was triturated sequentially with hexane (25 mL), CH₂Cl₂ (25
120 mL) and MeOH (25 mL), to afford individual fractions of 71.2 mg, 56.3 mg and 13.6 mg

¹ See supporting information of: Raju, R., Piggott, A. M., Huang, X.-C., and Capon, R. J. Nocardioazines: A Novel Bridged Diketopiperazine Scaffold from a Marine-Derived Bacterium Inhibits P-Glycoprotein, *Org. Lett.* **2011**, *13*, 2770-2773.

121 respectively. Fractions were concentrated to dryness in vacuo, and the CH₂Cl₂ fraction was
122 subsequently subjected to HPLC fractionation (Zorbax CN 5 μm, 250 × 9.4 mm column, 4
123 mL/min gradient elution from 60% H₂O/MeOH to 100% MeOH over 55 min, with a hold at
124 100% MeCN for 5 min) to yield multiple metabolites as described in section **S10**. Genomic DNA
125 was isolated from *Nocardioopsis sp.* CMB M0322 and was subjected to sequencing.

126 **S3. Draft Genome Sequencing of *Nocardioopsis sp.* CMB M0322 and Pathway** 127 **Annotation, Cloning and Heterologous expression**

128
129 The draft genome sequence and assembly of *Nocardioopsis sp.* CMB-M0232 was completed by
130 Cofactor Genomics (St. Louis, MO) through a combination of Illumina and 454 sequencing
131 technologies. Open reading frames (ORFs) were predicted using GeneMark Version 2.5.
132 BLASTP searches were employed to determine ORFs with homology to those in the NCBI
133 database.

134 ***Construction of *Nocardioopsis sp.* CMB-M0232 cosmid clone library***

135 A ~2,000-member cosmid clone library of *Nocardioopsis sp.* CMB-M0232 gDNA was prepared
136 using SuperCos 1 vector and following manufacturer protocols (Agilent Technologies). Briefly, gDNA
137 was digested with Sau3A1 to afford ~30-50kB fragments, which were ligated into SuperCos 1. MaxPlax
138 lambda packaging extracts (EpiCenter) were used to package constructs, which were introduced into *E.*
139 *coli* XL1-MRF for propagation. Individual members of the clone library were stored at -80 °C as
140 glycerol-preserved stocks in 96-well microtiter plates.

141 ***Screening of cosmid clone library for contig #1 gene cluster***

142 To identify cosmid library members carrying contig #1, clones from individual microtiter plates

143 were pooled and screened by PCR using the primer pair CDPS1F (5'-
144 GTCGGTGACGAGCCATGCCC-3') and CDPS1R (5'-CTTCGCGCAACGCGCCAAAT-
145 3'), which flank *nozA*. Each PCR contained 20.2 μ L of molecular biology grade water, 2.5 μ L of 10X
146 ThermoPol buffer, 0.5 μ L of dNTPs (200 μ M of each dNTP), 1 μ L DMSO, 0.1 μ L of each primer (0.4
147 μ M), 0.5 μ L of template, and 0.1 μ L of ThermoPol Taq polymerase (New England Biolabs). PCR was
148 conducted with an initial denaturation cycle of 94 $^{\circ}$ C for 3:00, followed by 30 cycles of 94 $^{\circ}$ C for 45s, 60
149 $^{\circ}$ C for 60 s, and 72 $^{\circ}$ C for 60 s, a final extension cycle of 72 $^{\circ}$ C for 5 min. Once plates containing contig
150 #1 were identified, clones from individual rows and columns within these plates were pooled and re-
151 screened to determine the specific well(s) containing cosmids with contig #1. For each resulting clone
152 (e.g. pAL557), sequencing of ~2 kB of each end of the gDNA insert was conducted to verify the entirety
153 of contig #1 was contained within the insert.

154 ***Adaptation of cosmid construct for expression of contig #1 and introduction into S. coelicolor M1146***

155 The SuperCos 1 cosmid clone pAL557, carrying contig #1, was adapted for introduction into and
156 expression in *Streptomyces* hosts by following the method described by Smanski et al.² Specifically,
157 pAL557 was modified by using λ -RED *E. coli* recombination approaches to introduce an origin of
158 conjugal transfer (*oriT*), *Streptomyces* θ C31 integrase for integration into the *attB* site of the *Streptomyces*
159 chromosome, and an apramycin resistance gene (*aac(3)IV*). Using previously described methods and
160 primers 3'AmpF and 3'AmpR,² a 270 bp fragment from the 3'-end of the *bla* gene from SuperCos 1 was
161 PCR amplified and cloned into the XbaI/BamHI site of *Streptomyces*-integrating pSET152 vector,³ which
162 encodes *aac(3)IV*, *oriT*, and θ C31 integrase. The resulting pSET152/3'bla construct was then linearized
163 by digestion with BamHI and EcoRI. This linear construct was introduced into λ -RED recombination
164 proficient *E. coli* BW25113/pIJ790 carrying pAL557, to afford homologous recombination between the

² M. J. Smanski, J. Casper, R. M. Peterson, Z. Yu, S. R. Rajski and B. Shen, *J. Nat. Prod.* **2012**, *75*, 2158-2167.

³ M. Bierman, R. Logan, K. O'Brien, E. Seno, R. Rao and B. Schoner, *Gene*, 1992, **116**, 43-49.

165 homologous pUC site and 3'-*bla* end. This yielded pAL5571, for which the presence of *aac(3)IV*, *oriT*,
166 and θ C31 integrase was confirmed by PCR and DNA sequencing. pAL5571 was introduced into *S.*
167 *coelicolor* M1146 by interconjugal transfer from *E. coli* ET12567/pUZ8002 using standard methods.⁴
168 Integration of pAL5571 contig #1 genes into the *S. coelicolor* M1146 chromosome was confirmed by
169 PCR amplification and sequencing of selected genes spanning the entire contig. The gDNA insert size
170 was approximated by restriction digesting pAL5571 with BamHI and evaluating resulting DNA fragment
171 sizes by agarose gel electrophoresis.

172 ***Cultivation and chemical extraction of S. coelicolor M1146***

173 Fifty microliters of *S. coelicolor* M1146/pAL5571 6-day starter culture in M1 media was used to
174 inoculate 10 mL of M1 media (without Instant Ocean) supplemented with 50 µg/mL apramycin in 50 mL
175 Falcon tubes. Control cultures were equivalently prepared using *S. coelicolor* M1146 and omitting
176 apramycin. Cultures were incubated at 30 °C with shaking at 225 rpm for six days. Treatment and
177 control fermentations were conducted in triplicate. Cultures were extracted with 10 mL EtOAc and the
178 resulting chemical extracts concentrated to dryness *in vacuo*. Chemical extracts were resolubilized with
179 100 µL of MeOH for analysis by HPLC and LC/MS.

180 ***Evaluation of chemical profiles of S. coelicolor M1146/pAL5571 treatments and M1146 controls***

⁴ (a) J. P. Gomez-Escribano and M. J. Bibb, *Microbiol. Biotechnol.* **2011**, *4*, 207-215.

(b) T. Kieser, M. J. Bibb, M. J. Buttner, K. F. Chater and D. A. Hopwood, *Practical Streptomyces Genetics*, The John Innes Foundation, Norwich, 2000.

181 Metabolite profiles were compared between treatment and control cultures by HPLC and
182 LC/MS. Twenty microliters of each treatment and control extract (n=3) were analyzed by HPLC
183 with diode array detection, and two microliters were evaluated by LC/MS. HPLC was
184 conducted using an Agilent 1100 HPLC system with diode array detector, Agilent Zorbax SB-
185 C18 column (4.1 × 150 mm, 5 μm), and a flow rate of 0.75 mL/min. Elution began with a hold
186 at 80/20 H₂O/ACN for 3 min, then a linear gradient from 80/20 to 10/90 H₂O/ACN over the next
187 22 min, followed by a linear gradient from 10/90 H₂O/ACN to 100% ACN over the next 2 min,
188 and a final hold at 100% ACN for 5 min. Chemical profiles were compared using ChemStation
189 (Agilent). LC/MS analyses were conducted as described elsewhere in Methods.

190 **S4. General Experimental and Instrumentation**

191

192 **I. Reagents, Solvents and Glassware.** All small-scale dry reactions were carried out under
193 a blanket of nitrogen, using standard syringe-septum, and cannulation techniques.⁵ AIBN was
194 recrystallized from ether and stored at 0-5 °C in an amber bottle. Dry THF was obtained by
195 distillation over sodium-benzophenone ketyl. Dry triethyl amine and diisobutyl ethyl amine was
196 obtained after distillation over KOH. Dry dichloromethane and dry DMF were prepared by
197 distilling over calcium hydride. Anhydrous ether and hexanes were obtained from an m-Braun
198 solvent purification system (charged with A2 alumina as a desiccant).⁶ All other solvents were
199 purified according to specific literature procedures.⁷

⁵ Pirrung, M. C.; Chapter 8: Conducting the Reaction Itself, *The Synthetic Organic Chemist's Companion*, John Wiley & Sons Inc., Hoboken, NJ, 2007, 69-91.

⁶ Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K. Timmers, F. J. Safe and Convenient Procedure for Solvent Purification. *Organometallics*, **1996**, *15*, 1518 -1520.

200 **II. Chromatography.** Analytical thin-layer chromatography (TLC) was performed with
201 silica Gel 60 Å (230-400 mesh) specifically to monitor the progress of each chemical reaction
202 and used as a guide for purification of the ensuing mixtures. These were conducted on glass
203 plates (7.5 x 2.5 and 7.5 x 5.0 cm) coated with silica gel G containing 13% calcium sulphate as
204 binder or on pre-coated 0.2 mm thick 60 F₂₅₄ silica plates and various combinations of ethyl
205 acetate and hexane were used as eluent. Visualization of spots after TLC was accomplished by
206 exposure to iodine vapour and/or UV light (254 nm). All compounds were purified using flash
207 column chromatography⁸ (Silica gel grade: 200-400 mesh, 40-63 µm) at medium pressure (20
208 psi). Preparatory thin-layer chromatography (TLC) (to obtain purified compounds) for select
209 products were performed on glass plates (7.5 x 2.5 and 7.5 x 5.0 cm) coated with 60 Å silica gel.
210 Yields refer to compounds isolated to analytical purity after chromatography.

211 **III. Structural Characterization of Synthetic and Biosynthetic Intermediates.** NMR
212 spectroscopic analyses (¹H NMR, ¹³C NMR) were conducted for all new compounds. ¹H (400
213 MHz) and ¹³C (100 MHz) spectra were recorded on a 400 MHz spectrometer, with the exception
214 of a few compounds recorded on a 600 MHz spectrophotometer (¹H: 600 MHz and ¹³C: 150
215 MHz). Pertinent frequency is specifically reported for each compound. Chemical shift values (δ)
216 for NMR spectra are reported in parts per million (ppm) relative to the residual (indicated)
217 solvent peak (CDCl₃ or CD₃OD). Additional peaks other than the compound in question, if any,
218 are calibrated based on reported values for trace impurities.⁹ Coupling constants are reported in







⁷ Armarego, W. L. F.; Chai, C. L. L.; *Purification of Laboratory Chemicals*, 5th Ed. Elsevier Butterworth-Heinemann, 2003.

⁸ Still, W. C.; Kahn, M.; Mitra, A. Rapid chromatographic technique for preparative separations with moderate resolution. *J. Org. Chem.* **1978**, *43*, 2923-2925.









⁹ (a). Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities *J. Org. Chem.* **1997**, *62*, 7512-7515 and (b). Fulmer, G. R.; Miller, A. J. M.; Sherden, N. H.; Gottlieb, H. E.; Nudelman, A.; Stoltz, B. M.; Bercaw, J. E.; Goldberg, K. I. NMR Chemical Shifts of Trace Impurities: Common









219 Hz. Data for ^1H NMR are reported as follows: chemical shift (δ , ppm), multiplicity (s = singlet,
220 brs = broad singlet, d = doublet, t = triplet, q = quartet, ddd = double double doublet, m =
221 multiplet, cm = complex multiplet), integration corresponding to the number of protons followed
222 by coupling constants in Hz. For ^{13}C NMR spectra, the nature of the carbons (C, CH, CH₂ or
223 CH₃) was determined by recording the Distortionless Enhancement by Polarization Transfer
224 (DEPT) experiment, and notations are provided in parentheses. ^{13}C NMR data is reported in parts
225 per million (δ) relative to the residual (indicated) solvent peak. All melting points for solids were
226 determined on a Buchi B-540 instrument and are reported uncorrected. pH determination was
227 performed with a standard pH meter. IR spectra were recorded on a FT-IR spectrophotometer.
228 Chiroptical measurements ($[\alpha]_D$) were obtained on a polarimeter in a 100 × 2 mm cell. Chiral
229 HPLC analyses for enantio-enriched synthetic intermediates were performed using a Shimadzu
230 LC-20-AT Series separations module equipped with Shimadzu SPD-M20A PDA (photo diode
231 array) multiple wavelength detector (180nm-800nm). The overall system, CBM-20 was
232 controlled using LC Solutions software. Raw data was plotted using Origin[®] software program
233 after exporting absorbance data as an ASCII-formatted file. Analytical separations of
234 enantioenriched mixtures were carried out on Daicel[®] (normal phase) AS chiral column. High-
235 resolution mass spectrometry (HRMS) data for synthetic compounds reported herein were
236 obtained by direct infusion of methanolic solutions on a HDMS QTOF mass spectrometer.
237 Accurate LC-MS-MS data of biological extracts were recorded with a Waters Acquity I-Class
238 UPLC system and a Waters Synapt G2 HDMS mass spectrometer as described in **Section S10**.
239









240 **Table S1**¹⁰. List of chemical structures and corresponding numbers assigned.241
242








Compound #	Structure	Published / reference name given in this study
1		nocardioepsin A
2		nocardioepsin B
3		nocardioazine A
4		nocardioazine B
5* and (ent-5)*		<i>cyclo</i> -L-Trp-L-Trp DKP and <i>cyclo</i> -D-Trp-D-Trp DKP
6		<i>cyclo</i> -L-Trp-D-Trp DKP

¹⁰ Note: Synthetic targets assembled in this study as putative intermediates in nocardioazine biosynthetic pathway are denoted by *.

7		Late stage epoxide intermediate
8 and <i>ent</i> -8		N-Cbz-L-Trp-acid or N-Cbz-D-Trp-acid
9 and <i>ent</i> -9		L-Trp methyl ester or D-Trp methyl ester
10 and <i>ent</i> -10		L-Trp-N-Cbz-L-Trp-COOMe-dimer or D-Trp-N-Cbz-D-Trp-COOMe-dimer
11 and <i>ent</i> -11		L-Trp-L-Trp-COOMe-dimer or D-Trp-D-Trp-COOMe-dimer
12*		<i>cyclo</i> -L-Trp- C3'-prenyl-L-Trp DKP
13*		<i>cyclo</i> -C3-Me-L-Trp -L-Trp DKP
14*		<i>cyclo</i> -N1ϕ-Me-L-Trp-L-Trp DKP


15*		<i>cyclo</i> -L-Trp-N1'-Me-C3'-prenyl-L-Trp DKP
16*		<i>cyclo</i> -C3-Me-L-Trp-N1'-Me-L-Trp DKP
17*		Des-N1'-Me-nocardioazine B
18		C3-Methyl-indole
19		Methyl 2-(benzyloxy)carbonyl-amino acrylate
20a, b		(2S,3aR,8aR)-1-((benzyloxy)carbonyl)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylic acid methyl ester
20c		(2S,3aR,8aR)-1-((benzyloxy)carbonyl)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylic acid
21		<i>N</i> -Me-L-Trp-Methyl Ester

22		Benzyl-(2S,3aR,8aR)-2-((3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)carbamoyl)-3a-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate
23		Methyl((2S,3aR,8aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carbonyl)tryptophanate
24		Benzyl-(2S,3aR,8aR)-2-((1-methoxy-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-3a-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate
25		N-methyl-(2S,3aR,8aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carbonyl methyl-1-tryptophanate
26		N-Me-L-Trp-COOME ester
27a/b		C3'-prenyl-L-Trp-pyrroloindoline methyl ester
28a/b		N1'-Me-C3'-prenyl-L-Trp-pyrroloindoline methyl ester
29		N1'-phthalyl-L-Trp-acid


30		C3'- ⁿ prenyl-pyrroloindoline-methyl-ester-N1-phthalyl-L-Trp-amide
31		N1'-Me-C3'- ⁿ prenyl-pyrroloindoline-methyl-ester-N1-phthalyl-L-Trp-amide
32		L-Serine methyl ester hydrochloride
33		N-Cbz-L-Serine methyl ester
34		O-Boc-N-Cbz-L-Serine methyl ester
35		Methyl (S)-2-(1,3-dioxoisindolin-2-yl)-3-(1H-indol-3-yl)propanoate
36		N1-Me-N2-phth-L-Trp-methyl ester

244 **S6. Synthesis of *cyclo*-L-Trp-L-Trp DKP and *cyclo*-D-Trp-D-Trp DKP**

245



----- or -----



246

247 **L/D-Trp-N-Cbz-carbamate (8 or *ent*-8)¹¹**248 To a clear solution of L/D-Trp (500 mg, 2.45 mmol) in 20 mL of CH₃CN-H₂O (2:3) were added249 NaHCO₃ (308 mg, 3.68 mmol) and Na₂CO₃ (390 mg, 3.68 mmol). The resulting turbid solution250 (pH = 10~11) was cooled to 0 °C (H₂O/ice bath) and stirred for 15 min. To this mixture was

251 added Cbz-Cl (350 μL, 1.20 mmol) drop wise. The resulting solution was stirred for 15-20 min

252 at 0 °C, the ice bath was removed and reaction was stirred at rt for 3h, at which time no starting

253 material remained (TLC analysis). After acidification by drop wise addition of a 1 N HCl

254 solution and removal of CH₃CN by rotary evaporation, the reaction mixture was transferred to a

255 separatory funnel and washed three times with EtOAc. The combined organic phase was washed

256 with brine, dried over anhyd. Na₂SO₄, and filtered. Concentration under reduced pressure gave257 813 mg (98%) of 8 or *ent*-8 as a colorless powder which was directly used for the next step


258 without further purification. mp: 125-126 °C; IR (KBr): 3413, 3020, 2934, 1702, 1596, 1519,

259 1415, 1345, 1218, 1137, 1067, 760, 672 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ 7.58 (d, *J* = 8.0

¹¹ Shao, Y.-M.; Yang, W.-B.; Peng, H.-P.; Hsu, M.-F.; Tsai, K.-C.; Kuo, T.-H.; Wang, A. H.-J.; Liang, P.-H.; Lin, C.-H.; Yang, A.-S. and Wong, C.-H. *ChemBioChem* **2007**, 8, 1654–1657.

260 Hz, 1H), 7.33-7.23 (m, 7H), 7.06 (s, 1H), 7.09-7.02 (m, 1H), 6.95 (ddd, $J = 7.8, 7.0, 0.8$ Hz, 1H),
 261 5.04 (AB, $J = 12.5$ Hz, 1H), 4.98 (AB, $J = 12.5$, Hz, 1H), 4.42 (dd, $J = 7.4, 4.8$ Hz, 1H), 3.36
 262 (ABX, $J = 14.6, 4.8$ Hz, 1H), 3.14 (ABX, $J = 14.6, 7.5$ Hz, 1H). ^{13}C NMR (100 MHz, CD_3OD ,
 263 DEPT): δ 158.1 (C), 138.3 (C), 137.9 (C), 129.4 (2 * CH), 129.3 (C), 129.2 (C), 128.8 (CH),
 264 128.7 (CH), 124.4 (CH), 122.1 (CH), 119.6 (CH), 119.5 (2 * CH), 112.1 (CH), 111.7 (C), 67.3
 265 (CH_2), 57.8 (CH), 29.2 (CH_2). HRMS (EI, M^+): m/z calcd. for $\text{C}_{19}\text{H}_{18}\text{O}_4\text{N}_2$ 338.1267, found
 266 338.1262.

267



268



269

270 L/D-Trp methyl ester hydrochloride (9 or *ent*-9)¹²

271 Thionyl chloride (7.15 mL, 98 mmol) was added drop wise to a cold ($0\text{ }^\circ\text{C}$) solution of
 272 anhydrous methanol (220 mL) under magnetic stirring. The solution was stirred at $0\text{ }^\circ\text{C}$ for 30

¹² This compound displayed satisfactory characterization data as published in the literature and was used without further purification or recrystallization: (a) Isaacs, N. S. and Coulson, M. Effect of pressure on processes modelling the Maillard reaction *J. Phys. Org. Chem.* **1996**, 9, 639-644. (b) Robaa, D.; Enzensperger, C.; AbulAzam, S. E.; Hefnawy, M. M.; El-Subbagh, H. I.; Wani, T. A. and Lehmann, J. Chiral Indolo[3,2-f][3]benzazecine-Type Dopamine Receptor Antagonists: Synthesis and Activity of Racemic and Enantiopure Derivatives *J. Med. Chem.* **2011**, 54, 7422-7426.

273 min. and then L/D-Trp (8.00 g, 39.2 mmol) was added and the resulting solution was heated at
274 60 °C for 18 h. After evaporation of the solvent, a white residue of hydrochloride salt was
275 obtained, which was neutralized by a satd. Na₂CO₃ solution (25 mL) and the ester was extracted
276 with equal volume of ethyl acetate three times. The organic layer was dried over anhyd. Na₂SO₄
277 and evaporated under reduced pressure yielding pale yellow oil, which solidified upon standing
278 to a pale yellow crystalline solid. Yield: 8.48 g (99%, 38.8 mmol) of L/D-Trp methyl ester (**9** or
279 *ent-9*). mp: 91-93 °C IR (KBr): 3386, 3017, 1730, 1582, 1441, 1351, 1215, 1101, 1014, 758, 665
280 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 8.27 (brs, 1H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.35 (td, *J* = 8.1,
281 0.9 Hz, 1H), 7.20 (ddd, *J* = 8.2, 7.1, 1.2 Hz, 1H), 7.13 (ddd, *J* = 8.0, 7.1, 1.1 Hz, 1H), 7.04 (d, *J* =
282 2.3 Hz, 1H), 3.85 (dd, *J* = 7.7, 4.8 Hz, 1H), 3.72 (s, 3H), 3.29 (ABXY, *J* = 14.4, 4.8, 0.8 Hz, 1H),
283 3.06 (ABXY, *J* = 14.4, 7.7, 0.4 Hz, 1H), 1.60 (brs, 2H). ¹³C NMR (100 MHz, CDCl₃, DEPT): δ
284 175.9 (C), 136.4 (C), 127.6 (C), 123.1 (CH), 122.3 (CH), 119.6 (CH), 118.7 (CH), 111.4 (CH),
285 111.2 (C), 55.1 (CH), 52.2 (CH₃), 30.8 (CH₂). HRMS (EI, M⁺): *m/z* calcd. for C₁₂H₁₄O₂N₂
286 218.1055, found 218.1055.




287

288 **Methyl ((benzyloxy)carbonyl)-L/D-tryptophyl-L/D-tryptophanate (10 or *ent-10*)**

289 To a cold ($-10\text{ }^{\circ}\text{C}$) magnetically stirred solution of *N*-Cbz-acid **8** or *ent*-**8** (400 mg, 1.18 mmol)
290 with D/L-Trp-methyl ester (*ent*-**9** or **9**) (284.0 mg, 1.30 mmol) in dry THF (5.0 mL) was added
291 Et_3N (0.66 mL, 4.73 mmol) followed by BOP-Cl (903 mg, 3.55 mmol) and the resulting mixture
292 was stirred at same temperature overnight and was then quenched by addition of water (20 mL)
293 and extracted with ethyl acetate ($3 \times 20\text{ mL}$). The combined organic layer was washed with brine
294 and dried (anhyd. Na_2SO_4). Evaporation of the solvent under reduced pressure and purification
295 of the residue on a silica gel column using ethyl acetate–hexanes (1:1) as eluent furnished the
296 coupled-product **10** or *ent*-**10** as a colorless dense liquid in 93% yield (595 mg, 1.11 mmol). ^1H
297 NMR (400 MHz, CDCl_3): δ 7.80 (brs, 2H), 7.67 (d, $J = 8.2\text{ Hz}$, 1H), 7.37-7.27 (m, 7H), 7.25 (d,
298 $J = 8.4\text{ Hz}$, 1H), 7.20 (t, $J = 7.3\text{ Hz}$, 1H), 7.17-7.08 (m, 2H), 6.93 (t, $J = 7.3\text{ Hz}$, 1H), 6.89 (s,
299 1H), 6.55 (s, 1H), 6.15 (d, $J = 7.3\text{ Hz}$, 1H), 5.42 (d, $J = 7.6\text{ Hz}$, 1H), 5.08 (s, 2H), 4.79 (td, $J =$
300 7.8, 5.4 Hz, 1H), 4.51 (q, $J = 4.4\text{ Hz}$, 1H), 3.61 (s, 3H), 3.35 (ABX, $J = 13.7, 3.0\text{ Hz}$, 1H), 3.21-
301 3.05 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 171.9 (C), 171.1 ($2 \times$ C), 136.2 (C), 136.1
302 (C), 128.6 ($4 \times$ CH), 128.3 (CH), 128.1 ($2 \times$ CH), 127.4 (CH), 123.7 (CH), 123.1 (C), 122.3 (C),
303 122.2 ($2 \times$ CH), 119.9 (CH), 119.7 (CH), 119.0 (C), 118.5 (CH), 111.4 (CH), 111.3 (CH), 109.4
304 (CH), 67.0 (CH_2), 55.5 (CH_3), 52.8 (CH), 52.5 (CH), 28.6 (CH_2), 27.5 (CH_2). HRMS (EI, M^+):
305 m/z calcd. for $\text{C}_{31}\text{H}_{30}\text{O}_5\text{N}_4$ 538.2216, found 538.2182.

306



307

308

309 **Methyl L/D-tryptophyl-L/D-tryptophanate (11 or *ent*-11)**310 To a homogenous solution (under stirring with a magnetic bar) of coupling compound **10** or *ent*-311 **10** (235 mg, 0.44 mmol) in MeOH and ethyl acetate (1:1) was added 10% palladium on activated

312 charcoal (5 mg, 0.04 mmol) and the reaction mixture stirred under hydrogen at 1 atm for 7 h. The

313 solution was then filtered over a pad of celite and washed with ethyl acetate. Evaporation of the


314 solvent under reduced pressure yielded **11** or *ent*-**11** (98%, 173 mg, 0.43 mmol) in sufficiently

315 pure form as an off-white solid and was subjected to the next step. mp: 207 °C. IR (KBr): 3407,

316 3018, 2938, 1723, 1672, 1515, 1350, 1221, 1060, 757, 678 cm⁻¹. ¹H NMR (400 MHz, CD₃OD):317 δ 7.89 (s, 2H), 7.59 (td, *J* = 8.0, 1.0 Hz, 1H), 7.34 (td, *J* = 8.1, 1.0 Hz, 1H), 7.29 (td, *J* = 8.1, 1.0318 Hz, 1H), 7.24 (td, *J* = 8.0, 1.0 Hz, 1H), 7.10 (ddd, *J* = 8.0, 7.0, 1.0 Hz, 1H), 7.07 (s, 1H), 7.06-319 6.99 (m, 2H), 6.89 (ddd, *J* = 8.0, 7.0, 1.0 Hz, 1H), 6.85 (s, 1H), 4.72 (t, *J* = 6.0 Hz, 1H), 3.61 (s,320 3H), 3.59 (dd, *J* = 6.8, 5.6 Hz, 1H), 3.13 (ABXY, *J* = 14.6, 6.6, 0.6 Hz, 1H), 3.09 (ABXY, *J* =321 14.6, 5.6, 0.6 Hz, 1H), 3.03 (ABXY, *J* = 14.6, 5.6, 0.6 Hz, 1H), 2.98 (ABXY, *J* = 14.2, 6.6, 0.6322 Hz, 1H). ¹³C NMR (100 MHz, CD₃OD, DEPT): δ 177.1 (C), 173.7 (C), 138.1 (C), 137.9 (C),

323 128.9 (C), 128.6 (C), 124.9 (CH), 124.5 (CH), 122.5 (CH), 122.4 (CH), 119.8 (CH), 119.8 (CH),

324 119.5 (CH), 119.2 (CH), 112.3 (CH), 112.3 (CH), 110.9 (C), 110.1 (C), 56.4 (CH), 54.4 (CH),
 325 52.7 (CH₃), 31.6 (CH₂), 28.4 (CH₂). HRMS (EI, [M-NH₃]⁺): m/z calcd. for C₂₃H₂₁O₃N₃
 326 387.1583, found 387.1585.




329 A homogenous solution (under stirring with a magnetic bar) of amine **11** or *ent-11* (396 mg, 0.98
 330 mmol) was refluxed overnight in 14 M methanolic ammonia (15.0 mL). Evaporation of the
 331 solvent under reduced pressure and washing of the resulting residue with chloroform furnished
 332 the pure diketopiperazine **5** or *ent-5* (345 mg, 95% yield, 0.93 mmol) as a pale yellow solid. mp:
 333 242 °C. IR (KBr): 3409, 3326, 3018, 2926, 2481, 1659, 1536, 1453, 1336, 1225, 1088, 1018,
 334 932, 758, 669 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ 7.45 (td, *J* = 8.0, 1.0 Hz, 2H), 7.30 (td, *J* =
 335 8.0, 1.0 Hz, 2H), 7.09 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 2H), 7.01 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 2H), 6.46
 336 (s, 2H), 4.04 (dd, *J* = 6.7, 3.9 Hz, 2H), 2.92 (dd, *J* = 14.4, 3.8 Hz, 2H), 2.17 (dd, *J* = 14.4, 7.2 Hz,
 337 2H). ¹³C NMR (100 MHz, CD₃OD, DEPT): δ 169.7 (2 × C), 138.0 (2 × C), 128.6 (2 × C), 125.9
 338 (2 × CH), 122.5 (2 × CH), 120.1 (2 × CH), 119.7 (2 × CH), 112.4 (2 × CH), 109.4 (2 × C), 56.8
 339 (2 × CH), 31.4 (2 × CH₂). HRMS (EI, M⁺): m/z calcd. for C₂₂H₂₀O₂N₄ 372.1586, found
 340 372.1595. [α]_D²¹ - 52 (*c* 0.05, MeOH) for *cyclo-L-Trp-L-Trp* DKP (**5**) and [α]_D²¹ + 52 (*c*

341 0.05, MeOH) for *cyclo*-D-Trp-D-Trp DKP (*ent*-**5**)¹³. HPLC of individual enantiomer provided
 342 below in Fig. S14 and Fig S15.

343 **S7. Asymmetric Synthesis of *cyclo*-C3-Me-L-Trp-L-Trp DKP (**13**)**

344




345

346 ***L*-serine methyl ester hydrochloride¹⁴ (**32**)**

347 Thionyl chloride (3.79 mL, 52.0 mmol) was added drop wise to a cold (0 °C) solution of
 348 anhydrous methanol (50 mL) under magnetic stirring. The solution was stirred at 0 °C for 30 min
 349 and then *L*-Serine (5.0 g, 47.6 mmol) was added. The reaction mixture was stirred at room
 350 temperature for 24 h and TLC analysis (CHCl₃/CH₃OH, 9:1) indicated complete disappearance
 351 of *L*-serine. The reaction mixture was evaporated under reduced pressure and the residue was
 352 triturated with petroleum ether (~5 times) to provide 7.2 g (98%, 46.6 mmol) of *L*-serine methyl
 353 ester hydrochloride salt (**32**) as a colorless powder which was directly used in the subsequent
 354 step without further purification. mp: 161–162 °C; IR (KBr): 3402, 3024, 2951, 2691, 1739,
 355 1625, 1524, 1448, 1244, 1072, 893 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 4.13 (t, *J* = 3.8 Hz, 1H),
 356 4.01 (ABX, *J* = 11.9, 4.4 Hz, 1H), 3.91 (ABX, *J* = 11.9, 3.4 Hz, 1H), 3.85 (s, 3H). ¹³C NMR
 357 (100 MHz, CDCl₃, DEPT): δ 169.3 (C), 60.6 (CH₂), 56.1 (CH), 53.8 (CH₃). HRMS (ESI,
 358 M+H⁺): *m/z* calcd. for C₄H₁₀O₃N 120.0655, found 120.0660.

¹³ Data matched published report: Raju, R., Piggott, A. M., Huang, X.-C., and Capon, R. J. Nocardioazines: A Novel Bridged Diketopiperazine Scaffold from a Marine-Derived Bacterium Inhibits P-Glycoprotein, *Org. Lett.* **2011**, *13*, 2770-2773.

¹⁴ Gu, K.; Bi, L.; Zhao, M.; Wang, C.; Ju, J. and Peng, S. *Bioorg. Med. Chem.* **2007**, *15*, 6273–6290.




359

360 ***N*-Cbz-*L*-serine methyl ester (33)**

361 *L*-serine methyl ester hydrochloride (4.0 g, 25.7 mmol) was dissolved in a mixture of saturated
 362 NaHCO₃ (11.0 g in 50 mL H₂O) and CH₂Cl₂ (70.0 mL). To this solution, benzyl chloroformate
 363 (3.85 mL, 27.0 mmol) was added at 0 °C and the reaction mixture was stirred for 6 h at rt. After
 364 quenching the reaction with 1.0 M aqueous HCl at 0 °C, the organic layer was washed with water
 365 and brine and dried over anhyd. Na₂SO₄. The solvent was evaporated under reduced pressure,
 366 and the resultant residue was purified by column chromatography (EtOAc/hexane 1:1) to yield
 367 *N*-Cbz-*L*-serine methyl ester (**33**) (6.3 g, 24.9 mmol, 97% yield) as colorless oil. IR (KBr): 3393,
 368 3024, 2951, 1715, 1532, 1443, 1342, 1224, 1066, 893 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.40-
 369 7.27 (m, 5H), 5.75 (d, *J* = 6.56 Hz, 1H), 5.12 (s, 2H), 4.45 (dd, *J* = 7.80, 3.68 Hz, 1H), 5.05-3.85
 370 (m, 2H), 3.78 (s, 3H), 2.35 (t, *J* = 5.76 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃, DEPT): δ 171.1
 371 (C), 156.4 (C), 136.1 (C), 128.6 (2 × CH), 128.4 (2 × CH), 128.2 (CH), 67.3 (CH₂), 63.3 (CH₂),
 372 56.1 (CH), 52.9 (CH₃). HRMS (EI, M⁺): *m/z* calcd. for C₁₂H₁₅O₅N 253.0950, found 253.0954.

373



374


375

376 **Methyl 2-(benzyloxy)carbonyl-amino acrylate (19)**

377 To a homogenous solution (under stirring) of (6.3 g, 24.8 mmol) *N*-Cbz-L-serine methyl ester
378 (**33**) in dry CH₃CN (50 mL) was added DMAP (0.5 g, 4.1 mmol) followed by di-*tert*-butyl
379 dicarbonate (5.16 g, 23.6 mmol) under rapid stirring at room temperature. The reaction was
380 monitored by TLC (diethyl ether/*n*-hexane, 1:1) until all the reactants had been consumed. Tetra-
381 methyl guanidine (1.57 mL, 12.4 mmol) was added at room temperature and the reaction mixture
382 was further stirred overnight. Evaporation of the solvent at reduced pressure gave a residue that
383 was partitioned between diethyl ether (100 mL) and water. The organic phase was washed with
384 brine and dried (anhyd. Na₂SO₄). The solvent was evaporated under reduced pressure and the
385 residue was purified by column chromatography to yield the pure olefin product (**19**) (3.03 g,
386 12.9 mmol, 52% yield) as a colorless liquid. IR (KBr): 3402, 3024, 2951, 2691, 1719, 1640,
387 1522, 1448, 1320, 1210, 1072, 893 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.40-7.29 (m, 5H), 6.27
388 (s, 1H), 5.80 (d, *J* = 1.5 Hz, 1H), 5.17 (s, 2H), 3.81 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, DEPT):
389 δ 164.2 (C), 153.1 (C), 135.8 (C), 131.0 (C), 128.6 (2 × CH), 128.4 (CH), 128.3 (2 × CH), 106.1
390 (CH₂), 67.1 (CH₂), 53.0 (CH₃). HRMS (EI, M⁺): *m/z* calcd. for C₁₂H₁₃O₄N 235.0845, found
391 235.0845.

392 The intermediate *O*-Boc-*N*-Cbz-L-serine methyl ester (**34**) was characterized as a colorless
393 liquid. IR (KBr): 3366, 2972, 1735, 1524, 1453, 1366, 1274, 1165, 1075, 853 cm⁻¹. ¹H NMR
394 (400 MHz, CDCl₃): δ 7.38-7.28 (m, 5H), 5.61 (d, *J* = 8.3 Hz, 1H), 5.12 (s, 2H), 4.61 (dd, *J* = 8.4,
395 3.6 Hz, 1H), 4.48 (ABX, *J* = 11.2, 3.6 Hz, 1H), 4.34 (ABX, *J* = 11.2, 3.6 Hz, 1H), 3.78 (s, 3H),
396 1.46 (s, 9H). ¹³C NMR (100 MHz, CDCl₃, DEPT): δ 169.9 (C), 155.8(C), 153.1 (C), 136.1 (C),
397 128.6 (2 × CH), 128.3 (CH), 128.2 (2 × CH), 83.0 (C), 67.3 (CH₂), 66.2 (CH₂), 53.5 (CH), 53.0
398 (CH₃), 27.7 (3 × CH₃). HRMS (ESI, M+H⁺): *m/z* calcd. for C₁₇H₂₄O₇N 354.1547, found
399 354.1552.

400



401

402

403 **1-benzyl-2-methyl-(2R,3aR,8aR)-3a-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-**404 **1,2(2H)-dicarboxylate (20a)**405 Enantioselective formation of **20a** followed literature procedure reported by Repka et al.¹⁵

406 Accordingly, to a homogenous solution (under stirring) of 3-methyl indole (0.9 g, 6.86 mmol) in

407 dry CH₂Cl₂ (40.0 mL) was added (*S*)-BINOL (0.393 g, 1.37 mmol) and methyl 2-408 (benzyloxy)carbonyl-amino acrylate (**19**) (1.61 g, 6.86 mmol) followed by slow addition of409 SnCl₄ (1.2 equiv. in 1.0 M CH₂Cl₂) at room temperature over a period of 30 minutes and stirring

410 was continued for 4 h. To the reaction mixture 1M HCl was added and the organic layers

411 extracted with CH₂Cl₂. The organic phase was washed with brine and dried (anhyd. Na₂SO₄).

412 The solvent was evaporated under reduced pressure and the residue was purified by column

413 chromatography to yield the cyclic product **20** in 61% yield (1.54 g, 4.20 mmol). The product414 was detected to be present as a mixture of rotational isomers in 3:2 ratio as indicated by ¹H NMR


415 signals. IR (KBr): 3396, 3034, 2950, 1743, 1703, 1607, 1448, 1454, 1416, 1344, 1271, 1207,

416 1172, 1127, 1062, 1001, 959, 917, 818, 750, 696 cm⁻¹. **Data for major isomer:** ¹H NMR (400417 MHz, CDCl₃) δ 7.43-7.28 (m, 5H), 7.12-7.03 (m, 2H), 6.81-6.74 (m, 1H), 6.64 (d, *J* = 7.7 Hz,418 1H), 5.41 (brs, 1H), 5.27 (s, 1H), 5.19 (AB, *J* = 12.2 Hz, 1H), 4.93 (AB, *J* = 12.2 Hz, 1H), 4.11

¹⁵ Repka, L. M.; Ni, J.; Reisman, S. E. *J. Am. Chem. Soc.* **2010**, *132*, 14418-20.

419 (t, $J = 7.8$ Hz, 1H), 3.47 (s, 3H), 2.65 (ABX, $J = 12.9, 7.7$ Hz, 1H), 2.16 (ABX, $J = 12.9, 8.4$ Hz,
 420 1H), 1.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 173.1 (C), 154.3 (C), 147.9 (C), 135.8
 421 (C), 133.3 (C), 128.8 (CH), 128.4 (2 * CH), 128.2 (CH), 128.0 (2 * CH), 122.4 (CH), 119.3
 422 (CH), 109.9 (CH), 83.5 (CH), 67.3 (CH_2), 59.4 (CH), 52.2 (CH_3), 52.1 (C), 41.7 (CH_2), 24.1
 423 (CH_3). HRMS (EI, M^+): m/z calcd. for $\text{C}_{21}\text{H}_{22}\text{O}_4\text{N}_2$ 366.1580, found 366.1580.

424



425

426

427 **(2S,3aR,8aR)-1-((benzyloxy)carbonyl)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-**
 428 **b]indole-2-carboxylic acid (20c)**

429 To a homogenous solution (under stirring with a magnetic bar) of *N*-Cbz-methyl ester
 430 **20a** (373 mg, 1.02 mmol) in MeOH (7.0 mL) and THF (7.0 mL) was added aqueous solution of
 431 LiOH (98.0 mg, 4.0 mmol in 7.0 mL H_2O) and the reaction mixture stirred at room temperature
 432 overnight. It was then quenched with 1N HCl at 0 °C till the pH is between 4-5 followed by
 433 extraction with ethyl acetate (3×10 mL). The combined organic layers were washed with brine
 434 and dried (anhyd. Na_2SO_4). Evaporation of the solvent under reduced pressure and purification
 435 of the residue on a silica gel column using ethyl acetate–hexanes (1:1) as eluent furnished the
 436 acid **20c** in 69% yield (241 mg, 0.69 mmol).


437 **A similar prep was executed for synthesis of 20c on a gram-scale:** To a magnetically stirred
 438 solution of *N*-Cbz-methyl ester **20a** (1.0 g, 2.73 mmol) in MeOH (10.0 mL) and THF (10.0 mL)

439 was added excess aqueous solution of LiOH (656.0 mg, 10.0 mmol in 10.0 mL H₂O) and the
 440 reaction mixture stirred at room temperature overnight. It was then quenched with 1N HCl at 0
 441 °C till the pH of solution become 4-5 and extracted with ethyl acetate (3 × 50 mL). The
 442 combined organic layer was washed with brine and dried (anhyd. Na₂SO₄). Evaporation of the
 443 solvent under reduced pressure and purification of the residue on a silica gel column using ethyl
 444 acetate–hexanes (1:1) as eluent furnished the acid **20c** in 50% yield (480 mg, 1.36 mmol). Pale
 445 yellow liquid.

446 IR (KBr): 3391, 2961, 1701, 1608, 1462, 1414, 1354, 1317, 1205, 1157, 1127, 1050,
 447 1016, 978, 917, 746 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.45-7.36 (m, 2H), 7.33-7.20 (m, 3H),
 448 7.13-7.03 (m, 2H), 6.82-6.75 (m, 1H), 6.65 (d, *J* = 7.7 Hz 1H), 5.28 (s, 1H), 5.14 (AB, *J* = 12.4
 449 Hz, 1H), 5.01 (AB, *J* = 12.4 Hz, 1H), 4.18 (t, *J* = 8.0 Hz, 1H), 2.72 (ABX, *J* = 13.0, 8.1 Hz, 1H),
 450 2.22 (ABX, *J* = 13.0, 8.0 Hz, 1H), 1.41 (s, 3H). ¹³C NMR (100 MHz, CDCl₃, DEPT): δ 178.3
 451 (C), 154.5 (C), 147.9 (C), 135.9 (C), 133.3 (C), 129.0 (CH), 128.5 (2 × CH), 128.2 (CH), 127.7
 452 (2 × CH), 122.5 (CH), 119.4 (CH), 110.1 (CH), 83.8 (CH), 67.5 (CH₂), 59.2 (CH), 52.3 (C), 41.8
 453 (CH₂), 24.2 (CH₃). HRMS (ESI, M⁺): *m/z* calcd. for C₂₀H₂₀N₂O₄ 352.1423, found 352.1428.

454


455



457 **Benzyl-(2S,3aR,8aR)-2-((3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)carbamoyl)-3a-**
 458 **methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (22)**

459 To a homogenous solution of *N*-Cbz-acid (**20c**) (218.0 mg, 0.62 mmol) and L-Trp-methyl ester
460 hydrochloride (**9**) (151.0 mg, 0.69 mmol) in dry THF (4.0 mL) (under stirring with a magnetic
461 bar) at $-10\text{ }^{\circ}\text{C}$ was added Et_3N (0.38 mL, 2.75 mmol) followed by BOP-Cl (395.0 mg, 1.55
462 mmol) and the resulting mixture was stirred at $-10\text{ }^{\circ}\text{C}$ overnight. It was then quenched with
463 water (5.0 mL) and extracted with ethyl acetate ($3 \times 10\text{ mL}$). The combined organic layers were
464 washed with brine and dried (anhyd. Na_2SO_4). Evaporation of the solvent under reduced pressure
465 and purification of the residue on a silica gel column using ethyl acetate–hexanes (1:1) as eluent
466 furnished the coupled product (**22**) as a colorless dense liquid in 90% yield (306 mg, 0.55 mmol).
467 IR (KBr): 3359, 3012, 2960, 2927, 1684, 1612, 1519, 1418, 1349, 1216, 1155, 1127, 748 cm^{-1} .
468 ^1H NMR (400 MHz, CDCl_3): δ 8.54 (brs, 1H), 7.44 (d, $J = 7.8\text{ Hz}$, 1H), 7.38 (brs, 2H), 7.32 (d, J
469 $= 8.0\text{ Hz}$, 1H), 7.30-6.95 (m, 8H), 6.84 (d, $J = 2.2\text{ Hz}$, 1H), 6.76 (t, $J = 7.4\text{ Hz}$, 1H), 6.60 (d, $J =$
470 7.8 Hz , 1H), 5.40 (brs, 1H), 5.11 (s, 1H), 4.97 (AB, $J = 12.3\text{ Hz}$, 1H), 4.88 (AB, $J = 12.3\text{ Hz}$,
471 1H), 4.73 (q, $J = 5.6\text{ Hz}$, 1H), 3.93 (t, $J = 7.8\text{ Hz}$, 1H), 3.62 (s, 3H), 3.31 (dd, $J = 5.4, 2.3\text{ Hz}$,
472 1H), 3.17 (t, $J = 6.0\text{ Hz}$, 1H), 2.41 (dd, $J = 13.0, 7.8\text{ Hz}$, 1H), 2.09 (dd, $J = 13.0, 8.0\text{ Hz}$, 1H),
473 1.26 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 172.0 (C), 171.9 (C), 154.6 (C), 147.8 (C),
474 136.2 (C), 135.9 (C), 133.7 (C), 128.9 (CH), 128.4 (2 * CH), 128.1 (CH), 127.9 (2 * CH), 127.6
475 (C), 123.0 (CH), 122.4 (CH), 122.3 (CH), 119.7 (CH), 119.2 (CH), 118.4 (CH), 111.5 (CH),
476 109.7 (CH), 109.5 (C), 84.1 (CH), 67.2 (CH_2), 61.4 (CH), 52.9 (C), 52.3 (CH), 51.9 (CH_3), 42.2
477 (CH_2), 27.4 (CH_2), 23.8 (CH_3). HRMS (ESI, M^+): m/z calcd. for $\text{C}_{32}\text{H}_{32}\text{O}_5\text{N}_4$ 552.2373, found
478 552.2367.

479



480

481 **Methyl((2S,3aR,8aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-**482 **carbonyl)tryptophanate (23)**483 To a homogenous solution (under stirring) of coupling compound **22** (95.0 mg, 0.188 mmol) in

484 MeOH and ethyl acetate (1:1) was added 10% palladium on activated charcoal (18 mg, 0.017

485 mmol) and the reaction mixture stirred under hydrogen at 1 atm. for 7h. It was then filtered with


486 celite pad and washed with ethyl acetate. Evaporation of the solvent under reduced pressure

487 yielded 97% (70.0 mg, 0.167 mmol) of product **23** which was subjected for the next step without488 any purification. IR (KBr): 3359, 3012, 2960, 2927, 1684, 1519, 1418 cm^{-1} . ^1H NMR (400489 MHz, CDCl_3): δ 7.52 (d, $J = 7.9$ Hz, 1H), 7.38 (d, $J = 8.1$ Hz, 1H), 7.19-7.00 (m, 5H), 6.82 (t, $J =$ 490 7.4 Hz, 1H), 6.68 (d, $J = 7.9$ Hz, 1H), 5.20 (s, 1H), 4.84 (dd, $J = 9.6, 5.0$ Hz, 1H), 3.84 (dd, $J =$ 491 $11.9, 5.9$ Hz, 1H), 3.70 (s, 3H), 3.35 (ABX, $J = 14.6, 4.8$ Hz, 1H), 3.08 (ABX, $J = 14.6, 9.6$ Hz,492 1H), 2.23 (dd, $J = 13.2, 6.0$ Hz, 1H), 1.62 (t, $J = 12.8$ Hz, 1H), 1.30 (s, 3H). ^{13}C NMR (100 MHz,493 CDCl_3 , DEPT): δ 173.2 (C), 168.3 (C), 149.2 (C), 137.9 (C), 133.8 (C), 130.0 (CH), 128.7 (C),

494 124.6 (CH), 124.0 (CH), 122.4 (CH), 121.3 (CH), 119.9 (CH), 119.2 (CH), 112.4 (CH), 110.8

495 (C), 110.4 (CH), 85.2 (CH), 59.5 (CH), 55.5 (C), 54.8 (CH), 52.9 (CH_3), 44.1 (CH_2), 28.5 (CH_2),496 25.2 (CH_3). HRMS (ESI, M^+): m/z calcd. for $\text{C}_{24}\text{H}_{26}\text{O}_3\text{N}_4$ 418.2005, found: 418.2008.

497



498

499 **Cyclo-C3-Me-L-Trp-L-Trp DKP (13)**

500 To a homogenous solution (under stirring with a magnetic bar) of amine **23** (77.0 mg, 0.184

501 mmol) in 14 M methanolic ammonia (4.0 mL) was refluxed for overnight. Evaporation of the

502 solvent under reduced pressure and the residue was washed with chloroform furnished the pure

503 diketopiperazine **13** (44.0 mg, 68% yield) as a pale yellow color solid. IR (KBr): 3431, 3297,

504 3025, 1666, 1631, 1528, 1447, 1340, 1286, 1072, 911, 754, 625 cm^{-1} . ^1H NMR (600 MHz,

505 CD_3OD): δ 7.90 (s, 1H), 7.51 (dd, $J = 6.8, 1.5$ Hz, 1H), 7.11 (dd, $J = 7.1, 1.5$ Hz, 1H), 7.07-7.00

506 (m, 2H), 6.97 (dt, $J = 7.7, 0.8$ Hz, 1H), 6.93 (s, 1H), 6.85 (d, $J = 7.9$ Hz, 1H), 6.62 (t, $J = 7.4$ Hz,

507 1H), 6.39 (d, $J = 7.8$ Hz, 1H), 5.09 (s, 1H), 4.59 (brs, 1H), 4.23 (t, $J = 3.7$ Hz, 1H), 3.42 (ABX, J

508 = 14.7, 3.7 Hz, 1H), 3.08 (ABX, $J = 14.7, 4.3$ Hz, 1H), 2.38 (dd, $J = 12.0, 5.8$ Hz, 1H), 2.24 (dd,

509 $J = 12.4, 5.8$ Hz, 1H), 1.84 (t, $J = 12.0$ Hz, 1H), 1.28 (s, 3H). ^{13}C NMR (150 MHz, CD_3OD ,

510 DEPT): δ 171.0 (C), 168.1 (C), 150.0 (C), 137.6 (C), 133.0 (C), 129.2 (CH), 128.7 (C), 125.6

511 (CH), 123.1 (CH), 122.8 (CH), 120.1 ($2 \times$ CH), 119.2 (CH), 112.5 (CH), 110.7 (CH), 108.7 (C),


512 82.1 (CH), 59.4 (CH), 59.1 (CH), 51.9 (C), 43.1 (CH_2), 31.0 (CH_2), 24.7 (CH_3). HRMS (ESI,

513 $\text{M}+\text{H}^+$): m/z calcd. for $\text{C}_{23}\text{H}_{23}\text{O}_2\text{N}_4$ 387.1816, found 387.1824.

514

515 **S8. Asymmetric Synthesis of *cyclo*-C3-Me-L-Trp-N1'-Me-L-Trp DKP (16)**

516




517

518 **Methyl (S)-2-(1,3-dioxoisindolin-2-yl)-3-(1H-indol-3-yl)propanoate or N-phth-L-Trp-**
519 **methyl ester (35)**

520 To a refluxing solution of L-Trp-methyl ester (**9**) (1.0 g, 4.58 mmol) and phthalic anhydride
521 (0.747 g, 5.04 mmol) in toluene (35 mL) was added triethylamine (0.702 mL, 5.04 mmol) and
522 the reflux was continued overnight. Evaporation of the solvent under reduced pressure yielded
523 98% (1.57 g, 4.51 mmol) of product **35** which was subjected for the next step without any
524 purification as an orange fluffy solid. mp: 80 °C. IR (KBr): 3611, 3417, 2941, 1853, 1717, 1635,
525 1585, 1524, 1455, 1385, 1254, 1187, 1093, 1018, 880.6, 733.1 cm⁻¹. ¹H NMR (400 MHz,
526 CDCl₃): δ 7.84 (brs, 1H), 7.65 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.30 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.49
527 (ddd, *J* = 7.9, 6.8, 0.72 Hz, 1H), 7.16 (ddd, *J* = 8.0, 6.6, 0.96 Hz, 1H), 7.02 (ddd, *J* = 8.1, 6.8, 1.1
528 Hz, 1H), 6.95 (ddd, *J* = 8.1, 6.9, 1.2 Hz, 1H), 6.89 (d, *J* = 2.4 Hz, 1H), 5.17 (dd, *J* = 9.5, 6.4 Hz,
529 1H), 3.69 (s, 3H), 3.65 (dd, *J* = 4.3, 0.92 Hz, 1H), 3.63 (dd, *J* = 2.0, 0.88 Hz, 1H). ¹³C NMR
530 (100 MHz, CDCl₃, DEPT): δ 169.7 (C), 167.6 (2 × C), 136.7 (C), 134.0 (2 × CH), 131.7 (2 × C),
531 127.6 (C), 127.3 (CH), 123.4 (2 × CH), 121.6 (CH), 119.0 (CH), 118.6 (CH), 109.5 (C), 109.2
532 (CH), 52.8 (CH), 32.6 (CH₃), 24.8 (CH₂). HRMS (EI, M⁺): *m/z* calcd. for C₂₀H₁₆N₂O₄ 348.1110,
533 found 348.1109.

534



535

536


537 **Methyl (S)-2-(1,3-dioxoisindolin-2-yl)-3-(1-methyl-1H-indol-3-yl)propanoate or N^1 -Me- N^2 -**
 538 **phth-L-Trp-methyl ester (36)**

539 To a cold (0 °C) solution of N -phth-L-Trp-methyl ester (**35**) (800 mg, 2.30 mmol) in dry DMF
 540 (8.0 mL) was added NaH (101 mg, 2.53 mmol) followed by slow addition of methyl iodide (215
 541 μL , 3.45 mmol) and the resulting mixture was stirred at same temperature for 8h (reaction
 542 monitored by TLC). It was then quenched with water (10 mL) and extracted with ethyl acetate (3
 543 \times 15 mL). The combined organic layer was washed with brine and dried (anhyd. Na_2SO_4).
 544 Evaporation of the solvent under reduced pressure and purification of the residue on a silica gel
 545 column using ethyl acetate–hexanes (1:20) as eluent furnished the product **36** in 58% yield (480
 546 mg, 1.32 mmol). Crystalline solid. mp: 124-125 °C; IR (KBr): 3026, 2952, 1745, 1714, 1614,
 547 1553, 1470, 1435, 1390, 1328, 1256, 1210, 1127, 1103, 1017, 967, 917, 880, 750, 720, 662 cm^{-1} .
 548 ^1H NMR (400 MHz, CDCl_3): δ 7.77 (dd, $J = 5.5, 3.0$ Hz, 2H), 7.67 (dd, $J = 5.5, 3.0$ Hz, 2H),
 549 7.59 (d, $J = 8.0$ Hz, 1H), 7.21 (d, $J = 8.2$ Hz, 1H), 7.15 (ddd, $J = 8.0, 6.8, 1.0$ Hz, 1H), 7.04 (ddd,
 550 8.0, 6.9, 1.2 Hz, 1H), 6.87 (s, 1H), 5.26 (dd, $J = 8.8, 7.1$ Hz, 1H), 3.79 (s, 3H), 3.74 (d, $J = 1.2$
 551 Hz, 1H) 3.72 (s, 1H), 3.65 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 169.8 (C), 167.7 (2 \times
 552 C), 136.9 (C), 134.1 (2 \times CH), 131.8 (2 \times C), 127.7 (C), 127.4 (CH), 123.5 (2 \times CH), 121.7

553 (CH), 119.0 (CH), 118.7 (CH), 109.6 (C), 109.2 (CH), 52.9 (CH), 52.8 (CH₃), 32.7 (CH₃), 24.9

554 (CH₂). HRMS (EI, M⁺): m/z calcd. for C₂₁H₁₈N₂O₄ 362.1267, found 362.1253.

555



556

557

558 **N-Me-L-Trp-Methyl Ester (21)**

559 To a solution of phthalyl amine (**36**) (525 mg, 1.45 mmol) in MeOH (7.0 mL) and CH₂Cl₂ (7.0

560 mL) was added hydrazine hydrate (78 μL, 1.59 mmol) and the reaction mixture stirred for 24h. It

561 was then filtered on a celite pad and washed with ethyl acetate. Evaporation of the solvent under

562 reduced pressure and purification of the residue on silica gel (pre-neutralized with Et₃N) column

563 using MeOH–CHCl₃ (1:20) as eluent furnished the amine (**21**) in (180 mg, 0.77 mmol) 54%

564 yield. IR (KBr): 3369, 2950, 2922, 1736, 1608, 1546, 1473, 1439, 1373, 1325, 1249, 1207, 1173,

565 1128, 1062, 1014, 837, 742 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.61 (td, *J* = 8.0, 1.0 Hz, 1H),

566 7.30 (td, *J* = 8.2, 1.0 Hz, 1H), 7.23 (ddd, *J* = 8.1, 6.9, 1.1 Hz, 1H), 7.12 (ddd, *J* = 8.0, 6.9, 1.1 Hz,

567 1H), 6.93 (s, 1H), 3.82 (dd, 7.7, 4.8 Hz, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 3.28 (ABXY, *J* = 14.4,

568 4.8, 0.8 Hz, 1H), 3.04 (ABXY, *J* = 14.4, 7.7, 0.6 Hz, 1H), 1.58 (brs, 2H). ¹³C NMR (100 MHz,


569 CDCl₃, DEPT): δ 175.9 (C), 137.1 (C), 128.0 (C), 127.8 (CH), 121.8 (CH), 119.1 (CH), 119.0

570 (CH), 109.7 (C), 109.4 (CH), 55.2 (CH), 52.1 (CH₃), 32.8 (CH₃), 30.7 (CH₂). HRMS (EI, M⁺):

571 m/z calcd. for C₁₃H₁₆O₂N₂ 232.1212, found 232.1208.

572

573



574

575


576 **Benzyl-(2S,3aR,8aR)-2-((1-methoxy-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-**577 **yl)carbamoyl)-3a-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (24)**

578

579 To a cold (0 °C) magnetically stirred solution of *N*-Cbz-acid **20c** (135.0 mg, 0.38 mmol) with *N*-
 580 Me-L-Trp-methyl ester **21** (98.0 mg, 0.42 mmol) in dry THF (3 mL) was added Et₃N (213.0 μL,
 581 1.53 mmol) followed by BOP-Cl (254.0 mg, 1.00 mmol) and the resulting mixture was stirred at
 582 room temperature for 12 h (reaction monitored by TLC). It was then quenched with water (3 mL)
 583 and extracted with ethyl acetate (3 × 10 mL). The combined organic layer was washed with brine
 584 and dried over anhyd. Na₂SO₄. Evaporation of the solvent under reduced pressure and
 585 purification of the residue on silica gel column using ethyl acetate–hexanes (1:3) as eluent
 586 furnished the coupled amide **24** in 81% yield (175 mg, 0.31 mmol) as a mixture of two
 587 rotational isomers. IR (KBr): 3381, 3019, 2954, 2927, 1740, 1692, 1610, 1515, 1481, 1465,
 588 1443, 1416, 1355, 1328, 1252, 1214, 1157, 1126, 1054, 1012, 986, 749, 696 cm⁻¹. ¹H NMR (400
 589 MHz, CDCl₃): δ 7.51 (d, *J* = 7.9 Hz, 0.5H), 7.40 (d, *J* = 8.1 Hz, 1H), 7.37 (s, 2H), 7.30-7.20 (m,
 590 5H), 7.20-7.05 (m, 5H), 6.99 (d, *J* = 7.5 Hz, 1H), 6.89 (s, 1H), 6.78-6.71 (m, 1.5H), 6.70 (s, 1H),
 591 6.59 (d, *J* = 7.8 Hz, 1H), 6.55 (d, *J* = 7.8 Hz, 0.5H), 6.43 (d, *J* = 8.0 Hz, 0.5H), 6.12 (d, *J* = 7.6

592 Hz, 1H), 5.41 (brs, 1H), 5.31 (AB, $J = 12.4$ Hz, 0.5H), 5.20 (s, 0.5H), 5.12 (s, 1H), 5.09 (AB, $J =$
 593 12.4 Hz, 0.5H), 4.96 (AB, $J = 12.4$ Hz, 1H), 4.89 (AB, $J = 12.4$ Hz, 1H), 4.67 (dd, $J = 12.8, 5.4$
 594 Hz, 1H), 4.07 (t, $J = 7.9$ Hz, 0.5H), 3.90 (t, $J = 7.9$ Hz, 1H), 3.73 (s, 1.5H), 3.72 (s, 3H), 3.68 (s,
 595 1.5H), 3.64 (s, 3H), 3.68-3.62 (m, 0.5H), 3.32 (t, $J = 4.8$ Hz, 0.5H), 3.17 (ABX, $J = 14.8, 5.5$ Hz,
 596 1H), 3.11 (ABX, $J = 14.8, 5.5$ Hz, 1H), 2.42 (ABX, $J = 13.0, 7.8$ Hz, 1H), 2.32 (ABX, $J = 13.0,$
 597 7.8, Hz, 0.5H), 2.21 (ABX, $J = 13.0, 7.0$ Hz, 0.5H), 2.10 (ABX, $J = 13.0, 8.2$ Hz, 1H), 1.34 (s,
 598 1.5H), 1.30 (s, 3.0H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 172.2 (C), 172.0 (C), 171.7 (C),
 599 171.2 (C), 154.8 (C), 154.6 (C), 147.8 (C), 147.2 (C), 136.9 (2 * C), 136.1 (C), 136 (C), 133.8
 600 (C), 133.6 (C), 128.9 (2 * CH), 128.6 (C), 128.5 (4 * CH), 128.4 (C), 128.1 (4 * CH), 128.0
 601 (CH), 127.9 (2 * CH), 127.4 (CH), 122.4 (CH), 122.3 (CH), 122.0 (CH), 121.8 (CH), 119.4
 602 (CH), 119.3 (CH), 119.2 (CH), 119.1 (CH), 118.7 (CH), 118.6 (CH), 109.8 (CH), 109.5 (CH),
 603 109.4 (CH), 109.3 (CH), 108.3 (C), 108.2 (C), 84.1 (CH), 83.8 (CH), 67.6 (CH_2), 67.1 (CH_2),
 604 61.8 (CH), 61.5 (CH), 53.3 (C), 52.8 (C), 52.7 (CH), 52.4 (CH_3), 52.3 (CH), 51.9 (CH_3), 42.1
 605 (CH_2), 41.4 (CH_2), 32.8 (2 * CH_3), 27.5 (CH_2), 27.3 (CH_2), 23.8 (CH_3), 23.6 (CH_3). HRMS (EI,
 606 M^+): m/z calcd for $\text{C}_{33}\text{H}_{34}\text{O}_5\text{N}_4$: 566.2529 found: 566.2529.

607




608 24

25

609 **N-methyl-(2S,3aR,8aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carbonyl)**
 610 **methyl-1-tryptophanate (25)**

611 To a magnetically stirred solution of **24** (75 mg, 0.13 mmol,) in MeOH (2 mL) and ethyl acetate
612 (1 mL) was added 10% palladium on activated charcoal (14 mg, 0.1 equiv.) and the reaction
613 mixture was stirred under hydrogen at 1 atm. Pressure for 6h. It was then filtered with Celite pad
614 and washed with ethyl acetate. Evaporation of the solvent under reduced pressure furnished the
615 amine **25** (57 mg, 0.13 mmol) in quantitative yield. The identity of the compound was confirmed
616 by HRMS and subjected for the next step without any purification. HRMS (EI, M⁺): m/z calcd.
617 for C₂₅H₂₈N₄O₃ 432.2161; found, 432.2164.



618

619

620 C3-Me-L-Trp- N1'-Me-L-Trp DKP (**16**)

621 To a magnetically stirred solution of amine (57 mg, 0.13 mmol) in 10M methanolic ammonia
622 (4.0 mL) was refluxed for overnight. Evaporation of the solvent under reduced pressure and the
623 residue was washed with chloroform furnished the pure diketopiperazine **16** (48 mg, 0.12 mmol)
624 in 91% yield. IR (KBr): 3431, 3297, 3025, 1666, 1631, 1528, 1447, 1340, 1286, 1072, 911, 754,
625 625 cm⁻¹. ¹H NMR (600 MHz, CD₃OD): δ 7.51 (d, *J* = 5.2 Hz, 1H), 7.10-7.07 (m, 2H), 7.06-
626 6.98 (m, 2H), 6.91 (d, *J* = 4.9 Hz, 1H), 6.86 (s, 1H), 6.65 (t, *J* = 4.9 Hz, 1H), 6.51 (d, *J* = 5.2 Hz,
627 1H), 5.15 (s, 1H), 4.59 (brs, 2H), 4.22 (s, 1H), 3.40 (s, 3H), 3.35 (dd, *J* = 9.8, 2.0 Hz, 1H), 3.12
628 (dd, *J* = 9.8, 3.0 Hz, 1H), 2.36 (dd, *J* = 7.9, 3.9 Hz, 1H), 2.25 (dd, *J* = 8.3, 3.9 Hz, 1H), 1.84 (t, *J*
629 = 8.1 Hz, 1H), 1.29 (s, 3H). ¹³C NMR (150 MHz, CD₃OD, DEPT): δ 170.8 (C), 168.2 (C), 150.2
630 (C), 138.0 (C), 133.2 (C), 129.8 (CH), 129.5 (C), 129.4 (CH), 123.4 (CH), 122.7 (CH), 120.3


631 (CH), 120.1 (CH), 119.7 (CH), 110.5 (CH), 110.3 (CH), 108.3 (C), 82.3 (CH), 59.6 (CH), 59.1
 632 (CH), 52.0 (C), 42.7 (CH₃), 32.9 (CH₂), 30.7 (CH₂), 24.9 (CH₃). HRMS (EI, M⁺): m/z calcd. for
 633 C₂₄H₂₄O₂N₄ 400.1899, found 400.1897.

634

635

636 **S9. Synthesis of *cyclo*-L-Trp-C3'-ⁿprenyl-L-Trp DKP (**12**) and *cyclo*-L-Trp-N1'-Me-C3'-
 637 ⁿprenyl-L-Trp DKP (**15**)**

638




639

640

641 To a magnetically stirred solution of L-Trp-methyl ester (**9**) (400 mg, 1.83 mmol) in sodium
 642 acetate-acetic acid solution (pH = 2.7) (30 mL) was added prenyl bromide (635 μ L, 5.50 mmol)
 643 over a period for 45-50 minutes at room temperature. The resulting mixture was stirred at same
 644 temperature for overnight. Evaporation of acetic acid under reduced pressure resulted in a solid
 645 residue which was dissolved in ethyl acetate. Solution was neutralized by addition of sodium
 646 carbonate solution and the ester was extracted with ethyl acetate three times. The combined
 647 organic layers were dried over anhyd. Na₂SO₄ and evaporated under reduced pressure yielding a
 648 diastereomeric mixture of the cyclic product **27a** and **27b** (in a 4:1 ratio) (358 mg, 1.25 mmol) in
 649 67% overall yield (based on recovered starting material). Data for major diastereomer **27a**: IR
 650 (KBr): 3366, 3044, 2933, 1823, 1737, 1672, 1605, 1477, 1365, 1225, 1110, 1024, 942, 833, 747
 651 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.06-7.01 (m, 2H), 6.72 (dt, J = 7.4, 0.9 Hz, 1H), 6.56 (d, J

652 = 7.9 Hz, 1H), 5.09 (t, $J = 7.3$ Hz, 1H), 4.91 (s, 1H), 3.71 (dd, $J = 10.5, 5.8$ Hz, 1H), 3.70 (s, 3H),
 653 3.42 (br's, 2H), 2.47-2.41 (m, 2H), 2.38 (dd, $J = 12.0, 5.8$ Hz, 1H), 2.00 (dd, $J = 12.0, 10.7$ Hz,
 654 1H), 1.68 (s, 3H), 1.55 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 174.4 (C), 150.0 (C),
 655 134.7 (C), 133.1 (C), 128.2 (CH), 123.6 (CH), 119.6 (CH), 118.8 (CH), 109.1 (CH), 82.2 (CH),
 656 59.4 (CH), 58.8 (CH_3), 52.2 (CH_2), 44.2 (C), 36.9 (CH_2), 26.0 (CH_3), 18.2 (CH_3). HRMS (ESI,
 657 $\text{M}+\text{H}^+$): m/z calcd. for $\text{C}_{17}\text{H}_{23}\text{O}_2\text{N}_2$ 287.1681, found 287.1758.




658
659

660 C3'-prenyl-pyrroloindoline-methyl-ester-N1-phthalyl-L-Trp-amide (30)

661 To a cold (0 °C) magnetically stirred solution of C3'-Prenyl-pyrrolo indole methyl ester **27a**
 662 (42.0 mg, 0.15 mmol) with L-Trp-N-phth-acid **29** (44.0 mg, 0.13 mmol) in dry THF (1.5 mL)
 663 was added Et₃N (101 μL , 0.73 mmol) followed by BOP-Cl (93 mg, 0.37 mmol) and the resulting
 664 mixture was stirred at room temperature for overnight. It was then quenched with water (10 mL)
 665 and extracted with ethyl acetate (3 \times 10 mL). The combined organic layer was washed with brine
 666 and dried (anhyd. Na_2SO_4). Evaporation of the solvent under reduced pressure and purification
 667 of the residue on a silica gel column using ethyl acetate–hexanes (4:6) as eluent furnished the
 668 coupling compound as a mixture of rotamers in 59 mg, 67% yield. The identity of the compound
 669 was confirmed by HRMS and subjected for the next step without any purification. IR (KBr):

670 3372, 3057, 2937, 1717, 1646, 1449, 1371, 1193, 1101, 913, 730 cm^{-1} . HRMS (ESI, $\text{M}+\text{Na}^+$):

671 m/z calcd. for $\text{C}_{36}\text{H}_{34}\text{O}_5\text{N}_4\text{Na}$ 625.2427, found 625.2441.




674 ***cyclo*-L-Trp-C3'-ⁿprenyl-L-Trp DKP (**12**)**

675 To a magnetically stirred solution of **30** (56 mg, 0.09 mmol) in MeOH (1.0 mL) and CH_2Cl_2 (1.0
 676 mL) was added hydrazine hydrate (45 μL , 0.93 mmol) and the reaction mixture stirred under
 677 nitrogen atmosphere for 24h. It was then quenched with water (10 mL) and extracted with ethyl
 678 acetate (3×10 mL). The combined organic layer was washed with brine and dried (anhyd.
 679 Na_2SO_4). Evaporation of the solvent under reduced pressure and purification of the residue on a
 680 silica gel column chromatography using EtOAc as eluent furnished the *cyclo*-L-Trp-C3'-
 681 ⁿprenyl-L-Trp DKP (**12**) in 70 % yield (29.0 mg, 0.06 mmol) as a single diastereomer. IR (KBr):
 682 3297, 3058, 1663, 1452, 1324, 1192, 1088, 922, 814, 740, 608 cm^{-1} . ^1H NMR (400 MHz,
 683 CDCl_3): δ 7.74 (brs, 1H), 7.59 (d, $J = 7.3$ Hz, 1H), 7.20 (m, 3H), 7.05 (dt, $J = 7.7, 1.2$ Hz, 1H),
 684 6.89 (d, $J = 6.9$ Hz, 1H), 6.86 (d, $J = 2.4$ Hz, 1H), 6.70 (t, $J = 7.4$ Hz, 1H), 6.40 (d, $J = 7.8$ Hz,
 685 1H), 6.04 (brs, 1H), 5.22 (s, 1H), 5.04 (t, $J = 7.3$ Hz, 1H), 4.44 (brs, 1H), 4.26 (dd, $J = 9.2, 4.0$
 686 Hz, 1H), 3.37 (ABX, $J = 14.6, 5.4$ Hz, 1H), 3.12 (ABX, $J = 14.6, 3.8$ Hz, 1H), 2.72 (dd, $J = 12.0,$
 687 5.5 Hz, 1H), 2.36-2.26 (m, 3H), 2.00 (t, $J = 12.0$ Hz, 1H), 1.65 (s, 3H), 1.49 (s, 3H).

688 ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 169.3 (C), 165.9 (C), 149.2 (C), 136.0 (C), 135.8 (C),
 689 131.0 (C), 128.3 (CH), 127.3 (C), 123.7 (CH), 123.3 (CH), 122.8 (CH), 120.0 (CH), 119.0 (CH),
 690 118.7 (CH), 118.5 (CH), 111.5 (CH), 109.3 (CH), 108.9 (C), 79.1 (CH), 58.5 (CH), 57.7 (CH),
 691 55.1 (C), 39.2 (CH_2), 35.5 (CH_2), 30.6 (CH_2), 26.1 (CH_3), 18.1 (CH_3). HRMS (ESI, $\text{M}+\text{Na}^+$):
 692 m/z calcd. for $\text{C}_{27}\text{H}_{28}\text{O}_2\text{N}_4\text{Na}$ 463.2110, found 463.2104.

693 **Asymmetric Synthesis of *cyclo*-L-Trp-N1'-Me-C3'-ⁿprenyl-L-Trp DKP (15)**

694




697 ***N*1'-Me-C3'-ⁿprenyl-L-Trp-pyrroloindoline methyl ester (28)**

698 To a magnetically stirred solution of *N*-Me-*L*-Trp-methyl ester **26** (680 mg, 2.93 mmol) in
 699 acetate-acetic acid solution (pH = 2.7) (30 mL) was added prenyl bromide (1.29 mL, 8.79 mmol)
 700 over a period for 45-50 minutes at room temperature. The resulting mixture was stirred at same
 701 temperature overnight. After evaporation of acetic acid under reduced pressure the resulting solid
 702 residue was dissolved in ethyl acetate. Then the mixture was neutralized through addition of
 703 sodium carbonate solution and the aqueous layer was extracted with ethyl acetate three times.
 704 The collected organic layer was dried over anhyd. Na_2SO_4 and evaporated under reduced
 705 pressure yielding diastereomeric mixture of the cyclic product in 11% yield for **28b** (99 mg, 0.33
 706 mmol) and 21% yield for **26a** (185 mg, 0.62 mmol) along with a 40% recovery of **26** amounting

707 to a 53% overall yield based on recovered starting material. **Data for diastereoisomer 28a:** IR
708 (KBr): 3366, 3044, 2933, 1823, 1737, 1672, 1605, 1477, 1365, 1225, 1110, 1024, 942, 833, 747,
709 662 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 7.08 (dt, $J = 7.7, 1.2$ Hz, 1H), 7.00 (dd, $J = 7.3, 1.2$ Hz,
710 1H), 6.63 (dt, $J = 7.4, 0.9$ Hz, 1H), 6.34 (d, $J = 7.8$ Hz, 1H), 5.09 (qt, $J = 6.7, 1.3$ Hz, 1H), 4.67
711 (s, 1H), 3.71 (s, 3H), 3.66 (dd, $J = 10.3, 6.2$ Hz, 1H), 3.08 (brs, 1H), 2.83 (s, 3H), 2.45-2.38 (m,
712 2H), 2.35 (dd, $J = 12.2, 6.2$ Hz, 1H), 2.00 (t, $J = 11.2$ Hz, 1H), 1.68 (s, 3H), 1.56 (s, 3H). ^{13}C
713 NMR (100 MHz, CDCl_3 , DEPT): δ 174.6 (C), 151.20 (C), 134.6 (C), 133.4 (C), 128.3 (CH),
714 123.0 (CH), 119.7 (CH), 117.0 (CH), 105.6 (CH), 88.8 (CH), 59.5 (CH), 57.1 (C), 52.2 (CH_3),
715 44.0 (CH_2), 36.7 (CH_2), 31.7 (CH_3), 26.0 (CH_3), 18.2 (CH_3). HRMS (EI, M^+): m/z calcd. for
716 $\text{C}_{18}\text{H}_{24}\text{O}_2\text{N}_2$ 300.1838, found 300.1838.

717 **Data for diastereoisomer 28b:** IR (KBr): 3366, 3044, 2933, 1823, 1737, 1672, 1605, 1477,
718 1365, 1225, 1110, 1024, 942, 833, 747, 662 cm^{-1} . ^1H NMR (400 MHz, CDCl_3): δ 7.05 (dt, $J =$
719 7.6, 1.2 Hz, 1H), 6.98 (dd, $J = 7.3, 0.9$ Hz, 1H), 6.60 (dt, $J = 7.4, 0.8$ Hz, 1H), 6.29 (d, $J = 7.8$
720 Hz, 1H), 5.13 (qt, $J = 6.7, 1.2$ Hz, 1H), 4.63 (s, 1H), 3.91 (dd, $J = 7.8, 3.1$ Hz, 1H), 3.50 (brs,
721 1H), 3.33 (s, 3H), 2.86 (s, 3H), 2.49-2.36 (m, 3H), 2.33 (ABX, $J = 12.8, 7.9$ Hz, 1H), 1.69 (s,
722 3H), 1.58 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3 , DEPT): δ 174.6 (C), 150.8 (C), 134.5 (C), 133.6
723 (C), 128.3 (CH), 123.2 (CH), 119.9 (CH), 117.0 (CH), 105.6 (CH), 88.7 (CH), 60.0 (CH), 56.0
724 (CH), 52.0 (CH_3), 41.0 (CH_2), 36.2 (CH_2), 31.4 (CH_3), 26.1 (CH_3), 18.2 (CH_3). HRMS (ESI,
725 M^+): m/z calcd. for $\text{C}_{18}\text{H}_{24}\text{O}_2\text{N}_2$ 300.1838, found 300.18375.

726




727

728

729 A cold (−10 °C) solution of *N*1'-Me-C3'-*n*-prenyl-*L*-Trp-pyrroloindoline methyl ester **28a** (100
 730 mg, 0.33 mmol) was mixed with *N*-Phth-*L*-Trp acid **29** (101, 0.30 mmol) under stirring in dry
 731 THF (8 mL) and Et₃N (168 μL, 1.21 mmol) was added followed by BOP-Cl (192 mg, 0.75
 732 mmol) and the resulting mixture was stirred at same temperature for 8 h. TLC was used for
 733 monitoring the progress. The reaction was then quenched with water (10 mL) and extracted with
 734 ethyl acetate (3 × 15 mL). The combined organic layers were washed with brine and dried over
 735 anhyd. Na₂SO₄. Evaporation of the solvent under reduced pressure and purification of the residue
 736 on a silica gel column using ethyl acetate–hexanes (1:20) as eluent furnished the coupled product
 737 **31** as a mixture of rotational isomers in 97% yield (180 mg, 0.29 mmol). This material was
 738 subjected to the DKP-forming step directly. HRMS (EI, M⁺): *m/z* calcd. for C₂₉H₃₂N₃O₃
 739 470.2444, found 470.2446.

740




741

742 **Cyclo-*L*-Trp-*N*1'-Me-C3'-*n*-prenyl-*L*-Trp DKP (15)**

743
744 To a magnetically stirred solution of **31** (180 mg, 0.29 mmol) in MeOH (5.0 mL) and CH₂Cl₂
745 (5.0 mL) was added hydrazine hydrate (152 μ L, 0.31 mmol) and the reaction mixture stirred
746 under nitrogen atmosphere for 24 h. It was then quenched with water (10 mL) and extracted with
747 ethyl acetate (3 \times 15 mL). The combined organic layers were washed with brine and dried
748 (anhyd. Na₂SO₄). Evaporation of the solvent under reduced pressure and purification of the
749 residue on preparative TLC using MeOH–CHCl₃ (1:40) as eluent furnished the Cyclo-*L*-Trp-
750 *N*1'-Me-C3'-*n*-prenyl-*L*-Trp DKP (**15**) in 74% yield (99.0 mg, 0.22 mmol). IR (KBr): 3308, 3243,
751 3059, 2927, 2864, 1788, 1670, 1501, 1442, 1359, 1305, 1233, 1172, 1104, 984, 919, 733 cm⁻¹.
752 ¹H NMR (600 MHz, CDCl₃): δ 8.21 (brs, 1H), 7.61 (d, *J* = 8.1 Hz, 1H), 7.39 (d, *J* = 8.1 Hz, 1H),
753 7.22 (t, *J* = 7.2 Hz, 1H), 7.21 (t, *J* = 7.4 Hz, 2H), 7.18 (brs, 1H), 7.00 (d, *J* = 7.3 Hz, 1H), 6.74 (t,
754 *J* = 7.2 Hz, 1H), 6.48 (d, *J* = 7.7 Hz, 1H), 5.98 (brs, 1H), 5.41 (s, 1H), 4.97 (t, *J* = 7.2 Hz, 1H),
755 4.43 (d, *J* = 7.6 Hz, 1H), 4.02 (dd, *J* = 11.0, 6.2 Hz, 1H), 3.68 (dd, *J* = 14.6, 3.1 Hz, 1H), 3.09 (s,
756 3H), 3.07 (dd, *J* = 14.6, 10.0 Hz, 1H), 2.52 (dd, *J* = 12.0, 6.0 Hz, 1H), 2.36-2.24 (m, 2H), 1.90 (t,
757 *J* = 12.0 Hz, 1H), 1.67 (s, 3H), 1.52 (s, 3H). ¹³C NMR (150 MHz, CDCl₃, DEPT): δ 168.8 (C),
758 165.4 (C), 136.6 (2 \times C), 135.6 (C), 131.8 (C), 129.0 (CH), 126.9 (CH), 124.0 (CH), 123.3 (CH),
759 122.9 (CH), 120.2 (CH), 120.1 (C), 118.9 (CH), 118.7 (CH), 111.6 (CH), 109.5 (CH), 109.0 (C),
760 85.6 (CH), 58.7 (CH), 55.0 (CH) 54.5 (C), 41.0 (CH₃), 36.7 (CH₂), 29.8 (CH₂), 28.5 (CH₂), 26.1
761 (CH₃), 18.2 (CH₃). HRMS (EI, M⁺): *m/z* calcd. for C₂₈H₃₀N₄O₂ 454.2369, found 454.2368.

762



763

764 **Des-N1'-Me-Nocardioazine B (17)**

765 To a magnetically stirred solution of *Cyclo*-C3-Me-L-Trp-L-Trp DKP (**13**) (88 mg, 0.23
 766 mmol) in sodium acetate-acetic acid solution (pH = 2.7) (5 mL) was added prenyl bromide (26.0
 767 μL , 0.23 mmol) drop wise over a period for 30-40 minutes at room temperature. The resulting
 768 mixture was stirred at same temperature for overnight. Evaporation of acetic acid under reduced
 769 pressure resulted in a solid residue which was dissolved in ethyl acetate. Solution was
 770 neutralized by addition of sodium carbonate solution and the prenylated DKP was extracted with
 771 ethyl acetate three times. The combined organic layers were dried over Na_2SO_4 and evaporated
 772 under reduced pressure yielding a diastereomeric mixture of Des-N1'-Me-Nocardioazine B (**17**)
 773 (in a 4:1 ratio) (73 mg, 0.16 mmol) in 71% overall yield (based on recovered starting material).
 774 Copies of NMR spectra reflect a mixture of inseparable diastereomeric mixture. IR (KBr): 3430,
 775 3298, 3026, 1667, 1631, 1529, 1447, 1340, 1286, 1072, 911, 754, 625 cm^{-1} . ^1H NMR (500 MHz,
 776 CDCl_3) (*major diastereomer*): δ 7.80 (s, 1H), 7.59 (dd, $J = 6.8, 1.5$ Hz, 1H), 7.20-7.00 (m, 3H),
 777 6.97 (dd, $J = 7.7, 0.8$ Hz, 1H), 6.93 (s, 1H), 6.70 (t, $J = 7.9$ Hz, 1H), 6.39 (d, $J = 7.4$ Hz, 1H),
 778 6.02 (brs, 1H), 5.19 (s, 1H), 4.40 (brs, 1H), 4.25 (t, $J = 3.7$ Hz, 1H), 3.79 (m, 1H), 3.62 (m, 1H),
 779 3.39 (ABX, $J = 14.7, 3.7$ Hz, 1H), 3.08 (ABX, $J = 14.7, 4.3$ Hz, 1H), 2.75 (dd, 14.7, 3.7 Hz, 1H),
 780 2.38 (dd, $J = 12.0, 5.8$ Hz, 1H), 1.84 (t, $J = 12.0$ Hz, 1H), 1.64 (s, 1H), 1.28 (s, 3H) 1.40 (s, 3H),
 781 1.38 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) (*major diastereomer*): 174.6; 170.5; 145.4; 134.0;

782 133.8; 132.8; 123.9; 123.3; 122.4; 120.5; 113.2; 80.7; 73.3; 72.8; 65.9; 63.3; 60.74; 50.46; 45.0;
783 38.9; 35.2; 31.0; 27.9; 27.5; 26.9; 23.9; 23.4; 18.1. HRMS (ESI, M+H⁺): m/z calcd. for
784 C₂₈H₃₁N₄O₂ 455.2469, found 455.2554.

785 **S10. Conditions for HRMS, HPLC, LC-MS and MS² Characterization and Identification**
786 **of signature peaks.**

787
788 A 2.1x50 mm column packed with BEH C18 1.7 μm particles (Waters) was held at 45 °C
789 throughout the separation; mobile phase A was 5% v/v Omnisolve grade CH₃CN (EMD
790 Millipore, Billerica, MA), 0.1% v/v formic acid (Sigma Aldrich) in Omnisolve grade water
791 (EMD). Mobile phase B was 5% v/v Omnisolve water, 0.1% v/v formic acid in acetonitrile and
792 the flow rate was maintained at 0.3 mL/min. The gradient profile was: Start at 10% B, linear
793 gradient to 100% B over 30 minutes, hold 3 minutes at 100% B, and a linear gradient to 0% B
794 over two minutes followed by a 3 minute re-equilibration period between injections. All effluent
795 was directed into the ESI source of the G2 (3.0 kV on capillary, 120 °C source temperature, 850
796 L/h of nitrogen desolvation gas @ 600 °C, 20 L/h of cone gas, 40 V on sample cone, 4 V on
797 extraction cone) which was used in resolution mode (20,000 resolving power). Separate
798 chromatograms were recorded simultaneously with a 0.2 sec MS1 scan from m/z 275-600 for the
799 LC eluent with no collision energy, along with nine 0.2 second MS-MS scans directing the
800 quadrupole to sequentially pass 205.10 (L/D-tryptophan, [M+H]⁺); 373.17 (*cyclo*-L-Trp-L/D-Trp
801 DKP (**5**), R_t for [M-H]⁻, 5.05 min and R_t for [M+H]⁺ 7.05 min.); m/z 387.18 (*cyclo*-C3-Me-L-
802 Trp-L-Trp DKP (**13**), M+H⁺, R_t 10.32 min.); m/z 401.19 (*cyclo*-C3-Me-L-Trp-N1'-Me-L-Trp
803 DKP (**16**), [M+H]⁺, R_t 12.15 min.); m/z 441.23 (*cyclo*-L-Trp-C3'-ⁿprenyl-L-Trp DKP (**12**),

804 [M+H]⁺, R_t 12.12 min.); m/z 455.24 (*cyclo*-L-Trp-N1'-Me-C3'-ⁿprenyl-L-Trp DKP (**15**), [M+H]⁺,
805 R_t 18.56 min. (17.25-19.25 min)); m/z 483.24 (nocardioazine A (**3**), [M+H]⁺, R_t 8.8 min.), 469.26
806 (nocardioazine B (**4**), [M+H]⁺, R_t 18.40 min.), and m/z 574.37 (nocardiopsin A (**1**), M+H⁺).


807 During the nine MS² experiments, the trap voltage (collision energy) was scanned from
808 20-50 V over 0.2 seconds; the trap was filled with 7.9*10⁻³ mbar of UHP Ar. The 9th
809 chromatogram was another MS1 scan of the lock spray nozzle which had 5 μL/min of a 2 mg/L
810 solution of Leucine-enkephalin (Sigma) in 50% v/v methanol, 0.1% v/v formic acid in water
811 using the m/z 556.2765 (M+H)⁺ ion to dynamically correct the mass axis calibration throughout
812 the experiment. After acquisition, extracted ion chromatograms for fragment ions were
813 generated using MassLynx 4.1 software (Waters). Each metabolite, synthesized or extracted was
814 observed and identified through MSM data. For example, the location of the methyl group of the
815 des-Me-nocardioazine B intermediates was determined by the presence of either 198.129 as the
816 base peak (indicating an H on N1') or 212.144 (indicating a CH3 on N1'). These identification
817 details are further elaborated in elsewhere.¹⁶


818

¹⁶ Srinivasan, J.; Porwal, S. K.; Alqahtani, N.; James, E. Bis, D. Lane, A. L.; Viswanathan, R.; Karty, J. K.;
“Collision-Induced Dissociation of Nocardioazines A and B and Related Tryptophan Cyclic Diketopiperazines”
Article *In preparation* for the Journal of the American Society for Mass Spectrometry.



819

820





822 **Figure S2.** Two diastereomers of *cyclo*-L-Trp-C3'-*n*-prenyl-L-Trp DKP (**12**) were
823 synthesized and their LC traces were seen as distinct peaks at R_t 9.37 (*minor*) and 12.11
(*major*) min respectively.



826 **Figure S3.** MS¹ and MS² for two diastereomers of *cyclo-L-Trp-C3'-ⁿprenyl-L-Trp DKP (12)*.

827

Table S2. MS² fragments for [M+H]⁺ peak at m/z = 373.1659 corresponding to *cyclo*-L-Trp-L-Trp DKP (**5**).

828

Observed Mass	% Rel. Int.	Predicted Mass	Mass Diff. (ppm)	Ion Composition
373.1662	2.8	373.1659	0.80	C ₂₂ H ₂₁ N ₄ O ₂ ⁺
242.0930	2.7	242.0924	2.48	C ₁₃ H ₁₂ N ₃ O ₂ ⁺
214.0980	1.6	214.0975	2.34	C ₁₂ H ₁₂ N ₃ O ⁺
169.0759	5.7	169.0760	-0.59	C ₁₁ H ₉ N ₂ ⁺
159.0924	2.5	159.0917	4.40	C ₁₀ H ₁₁ N ₂ ⁺
144.0809	1.3	144.0808	0.69	C ₁₀ H ₁₀ N ⁺
130.0654	100	130.0651	2.31	C ₉ H ₈ N ⁺
103.0544	2.8	103.0542	1.94	C ₈ H ₇ ⁺

829

830

831

Table S3. MS² fragments for [M+H]⁺ peak at m/z = 387.1816 corresponding to *cyclo*-C3-Me-L-Trp-L-Trp DKP (**13**).

832

833

Observed Mass	% Rel. Int.	Predicted Mass	Mass Diff. (ppm)	Ion Composition
387.1825	14.7	387.1816	2.32	C ₂₂ H ₂₁ N ₄ O ₂ ⁺
242.0936	3.0	242.0924	4.96	C ₁₃ H ₁₂ N ₃ O ₂ ⁺
184.0761	10.1	184.0757	2.17	C ₁₂ H ₁₀ NO ⁺
159.0923	3.2	159.0917	3.77	C ₁₀ H ₁₁ N ₂ ⁺
156.0815	3.9	156.0808	4.48	C ₁₁ H ₁₀ N ⁺
144.0813	100	144.0808	3.47	C ₁₀ H ₁₀ N ⁺
130.0656	24.5	130.0651	3.84	C ₉ H ₈ N ⁺
103.0547	1.0	103.0542	4.85	C ₈ H ₇ ⁺

834

835

836

Table S4. MS² fragments for [M+H]⁺ peak at m/z = 401.1972 corresponding to *cyclo*-C3-Me-L-Trp-N1'-Me-L-Trp DKP (**16**).

837

Observed Mass	% Rel. Int.	Predicted Mass	Mass Diff. (ppm)	Ion Composition
401.1981	8.8	401.1972	2.24	C ₂₄ H ₂₅ N ₄ O ₂ ⁺
384.1707	0.5	384.1707	0.00	C ₂₄ H ₂₂ N ₃ O ₂ ⁺
256.1089	1.0	256.1081	3.12	C ₁₄ H ₁₄ N ₃ O ₂ ⁺
201.1023	0.5	201.1022	0.50	C ₁₂ H ₁₃ N ₂ O ⁺
184.0761	2.6	184.0757	2.17	C ₁₂ H ₁₀ NO ⁺
173.1078	0.5	173.1079	-0.58	C ₁₁ H ₁₃ N ₂ ⁺
156.0813	0.8	156.0808	3.20	C ₁₁ H ₁₀ N ⁺
144.0813	100	144.0808	3.47	C ₁₀ H ₁₁ N ⁺

838

839

840

Table S5. MS² fragments for [M+H]⁺ peak at m/z = 441.2285 corresponding to *cyclo*-L-Trp-C3'-*n*-prenyl-L-Trp DKP (**12**) .

Observed Mass	% Rel. Int.	Predicted Mass	Mass Diff. (ppm)	Ion Composition
441.2292	1.5	441.2285	1.59	C ₂₇ H ₂₉ N ₄ O ₂ ⁺
385.1664	2.6	385.1659	1.30	C ₂₃ H ₂₁ N ₄ O ₂ ⁺
373.1665	3.6	373.1659	1.61	C ₂₂ H ₂₁ N ₄ O ₂ ⁺
271.1235	1.2	271.1230	1.84	see below
242.0930	2.3	242.0924	2.48	C ₁₃ H ₁₂ N ₃ O ₂ ⁺
198.1287	100	198.1277	5.05	C ₁₄ H ₁₆ N ⁺
183.1044	8.0	183.1043	0.55	C ₁₃ H ₁₃ N ⁺
168.0815	6.3	168.0808	4.16	C ₁₂ H ₁₀ N ⁺
156.0809	5.6	156.0808	0.64	C ₁₁ H ₁₀ N ⁺
144.0810	7.0	144.0808	1.39	C ₁₀ H ₁₀ N ⁺
130.0656	25.0	130.0651	3.84	C ₉ H ₈ N ⁺

841

842

843


844 **Table S6.** MS² fragments for [M+H]⁺ peak at m/z = 455.2442 corresponding to
 845 *Cyclo-L-Trp-M1'-Me-C3'-ⁿprenyl-L-Trp DKP (15).*

Observed Mass	% Rel. Int.	Predicted Mass	Mass Diff. (ppm)	Ion Composition
455.2435	0.8	455.2442	-1.54	C ₂₈ H ₃₁ N ₄ O ₂ ⁺
399.1806	2.1	399.1816	-2.51	C ₂₄ H ₂₃ N ₄ O ₂ ⁺
387.1823	2.0	387.1816	1.81	C ₂₃ H ₂₃ N ₄ O ₂ ⁺
285.1396	3.8	285.1387	3.16	C ₂₀ H ₁₇ N ²⁺
268.1089	2.1	268.1081	2.98	C ₁₅ H ₁₄ N ₃ O ²⁺
212.1441	100	212.1434	3.30	C ₁₅ H ₁₈ N ⁺
197.1207	9.7	197.1199	4.06	C ₁₄ H ₁₅ N ⁺⁺
182.0972	8.6	182.0964	4.39	C ₁₃ H ₁₂ N ⁺
158.0969	4.1	158.0964	3.16	C ₁₁ H ₁₂ N ⁺
144.0814	52.1	144.0808	4.16	C ₉ H ₈ N ⁺
130.0657	6.5	130.0651	4.61	C ₈ H ₇ ⁺


846

847


848



849



850



851

Figure S4. *cyclo-L-Trp-L-Trp* DKP (**5**). **A.** LC-ESI(-)-TOF-MSMS spectrum from *Nocardioopsis* sp. CMB-M0232. **B.** ESI(-) MS² for **5** extracted from *Nocardioopsis* sp. CMB-M0232. **C.** ESI(-) MS² for synthetic **5**.




Figure S5. LC-ESI(+)-TOF-MSMS traces from *Nocardiopsis* sp. CMB-M0232 confirming presence of tabulated metabolites as given in **Table 1** for $m/z = 373.2$ (**5**); 387.2 (**13**) and 574.4 (nocardiopsin A, * - pending full confirmation).





Figure S6. LC-ESI(+)-TOF-MSMS traces from *Nocardopsis sp.* CMB-M0232 confirming presence of tabulated metabolites as given in Table 1 for $m/z = 401.2$ (**16**); 455.3 (des-N1'-Me-nocardioazine B (**17**)) and 469.3 (nocardioazine B (**4**)).

858




859

860

Figure S7. ESI(+)-TOF MS¹ and MS² spectra spectra for m/z = 373.1665 (**5**) extracted from *Nocardioopsis* sp. CMB-M0232.

861




862

863

Figure S8. ESI(+)-TOF MS¹ and MS² spectra for $m/z = 387.1791$ (**13**) extracted from *Nocardiosis sp.* CMB-M0232. *cyclo*-C3-Me-L-Trp-L-Trp DKP (**13**) (7.7 ppm error) is shown with blue arrow, 387.2384 (148 ppm error) is not **13**, and is a different unidentified metabolite. Also, 387.2361 not fragmented during MSMS where *Cyclo*-C3-Me-L-Trp-L-Trp DKP (**13**) was totally fragmented in standard sample. Also, a coeluting, metabolite at $m.z$ 387.2361 was not fragmented. The presence of 144.0811 fragment (2.1 ppm error) indicates *cyclo*-C3-Me-L-Trp-L-Trp DKP (**13**).

864


865



866

867 **Figure S9.** LC-ESI+ TOF MSMS spectra for $m/z = 469.27$ (nocardioazine B, **4**) extracted from *Nocardopsis* sp. CMB-M0232.

868




869

870

Figure S10. Preliminary data for ESI(+)-TOF MS¹ and MS² spectra for $m/z = 469.27$; probably indicating nocardioazine B (**4**) from *Nocardopsis* sp. CMB-M0232.

871

872



873

874

875

876

877

878

879

880

881

882



883

884

885

Figure S11. TLC images of intermediates extracted from *Nocardiosis sp.* CMB M0322 corresponding to alkaloidal fractions. A1, B1 and C1 are synthetic standards of *Cyclo-C3-Me-L-Trp-L-Trp* DKP (**13**). A2 and A3 are extracts of *Nocardiosis sp.* CMB M0322 at 7 days from the time of inoculation. B2 and B3 are extracts of *Nocardiosis sp.* CMB M0322 at 14 days from the time of inoculation. C2 and C3 are extracts of *Nocardiosis sp.* CMB M0322 at 21 days from the time of inoculation. A4, B4 and C4 are co-spots between respective extracts and synthetic standard of **13**.

886



887 **NMR for compound from extract:**400 MHz, CD₃OD

888

889 **Figure S12.** ¹H NMR spectrum for **13** extracted from *Nocardiosis sp.* CMB-M0232 after 21 days of culture followed by fractionation and purification. Purification methods followed procedures adopted for the synthesis of **13** except culture extracts were used instead of crude reaction mixtures.

890

891




892

893

894

Figure S13. ¹³C NMR spectrum for **13** extracted from *Nocardioopsis* sp. CMB-M0232 – 6.9-7.15 ppm.

895


896 **S29. Cyclo-L-Trp-L-Trp-DKP (5) HPLC analysis**¹⁷

897

898

Figure S14. HPLC analyses of *cyclo-L-Trp-L-Trp-DKP (5)*.899 **S30. Cyclo-D-Trp-D-Trp-DKP (*ent-5*) HPLC analysis.**

900



902

Figure S15. HPLC analyses of *cyclo-D-Trp-D-Trp-DKP (ent-5)*.

903

¹⁷ A considerable asymmetry is noticeable in the HPLC traces and we attribute this to the fact that **5** and *ent-5* are polar entities and show significant “tailing” effect on a normal phase chiral AS column under the conditions observed.

904

905

906

907

908

909

910

911

912


913

914


915


916

S31. COPIES OF NMR SPECTRA





9
400 MHz, CDCl₃







9
100 MHz, CDCl₃






8
400 MHz, CD₃OD







8


100 MHz, CD₃OD







10
400 MHz, CDCl₃







10
400 MHz, CDCl₃







10
400 MHz, CDCl₃







10
100 MHz, CDCl₃







11
400 MHz, CD₃OD







11
400 MHz, CD₃OD







11
400 MHz, CD₃OD







11
400 MHz, CD₃OD







11
400 MHz, CD₃OD







11
400 MHz, CD₃OD







11
100 MHz, CD₃OD







5
400 MHz, CD₃OD







5
400 MHz, CD₃OD







5
400 MHz, CD₃OD







5
400 MHz, CD₃OD







5
400 MHz, CD₃OD








5
400 MHz, CD₃OD








5
100 MHz, CD₃OD













33


400 MHz, CDCl₃









34
400 MHz, CDCl₃










34

100 MHz, CDCl₃













20a
400 MHz, CDCl₃







20a
400 MHz, CDCl₃







20a
400 MHz, CDCl₃







20a
400 MHz, CDCl₃







20a
100 MHz, CDCl₃







20c
400 MHz, CDCl₃








20c
400 MHz, CDCl₃







20c
400 MHz, CDCl₃










22
400 MHz, CDCl₃







22
400 MHz, CDCl₃







22
400 MHz, CDCl₃







22
400 MHz, CDCl₃







22
100 MHz, CDCl₃







23
400 MHz, CD₃OD







23
400 MHz, CD₃OD







23
400 MHz, CD₃OD







23
400 MHz, CD₃OD







23
100 MHz, CD₃OD






13*
400 MHz, CD₃OD







13*
400 MHz, CD₃OD






13*
400 MHz, CD₃OD






13*
400 MHz, CD₃OD







13*
600 MHz, CD₃OD







13*
600 MHz, CD₃OD







13*
600 MHz, CD₃OD







13*
150 MHz, CD₃OD






13*
100 MHz, CD₃OD







16*
600 MHz, CD₃OD







16*
600 MHz, CD₃OD









16*
600 MHz, CD₃OD







16*
150 MHz, CD₃OD







24
400 MHz, CDCl₃







24
100 MHz, CDCl₃







35
400 MHz, CDCl₃







35
100 MHz, CDCl₃







36
400 MHz, CDCl₃






36
100 MHz, CDCl₃












26

400 MHz, CDCl₃













28a
100 MHz, CDCl₃









28b


400 MHz, CDCl₃







28b


400 MHz, CDCl₃







28b
400 MHz, CDCl₃







28b
100 MHz, CDCl₃







400 MHz, CDCl₃









15*
600 MHz, CDCl₃






15*
150 MHz, CDCl₃









15*


600 MHz, CDCl₃







15*


100 MHz, CDCl₃






27a
400 MHz, CDCl₃







27a


100 MHz, CDCl₃







17*
400 MHz, CDCl₃








17*
100 MHz, CDCl₃





















SKP-133 in CDC13

Sample Name:

Data Collected on:
1500-inova500
Archive directory:

Sample directory:


FidFile: PROTON

Pulse Sequence: PROTON (s2pu1)
Solvent: cdc13
Data collected on: MAR 20 2004

Temp. 25.0 C / 298.
Operator: efruchey

Relax. delay 10.000 sec
Pulse 45.0 degrees
Acq. time 2.049 sec
Width 7996.8 Hz
8 repetitions

OBSERVE H1, 499.8045972 MHZ
DATA PROCESSING
Line broadening 0.3 Hz
FT size 32768
Total time 1 min 37 sec



17

